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61. Abstract 
Anxiety disorders are characterized by an exaggerated fear response towards a non-harmful 
stimulus or situation. Exposure therapy is an effective treatment and consists of repeated 
non-reinforced exposures to the stimulus. Currently the index of beneficial learning is the de-
creased level of fear at the end of an exposure session. For patients this therapy is emotion-
ally very demanding and dropout rates are high. In addition, many patients are prone to re-
lapse in a context and time dependent manner.
In rodents, the explicit model for exposure therapy is extinction learning. After initial pair-
ing of a previous neutral stimulus (tone) with a negative outcome (shock), animals will show 
a directed fear reaction (conditioned response) during re-exposure. Multiple re-exposures of 
the animal to the stimulus without further reinforcement lead to a gradual decay of fear (ex-
tinction training). This fear decay is shown to be based on relearning processes. Over time the 
original memory trace of the tone predicting the shock is opposed and inhibited by the new 
association that the tone does not predict the shock any longer.
The focus of this work was to dissect extinction learning at the behavioural and the molecu-
lar level in a mouse model of conditioned fear. We want to critically revise nomenclature and 
to provide mechanistic insights and possible transfers to clinical application and to increase 
the persistence of fear extinction.
In the first set of experiments, we showed that fear deacy during exposure (within-session) to 
a permanent stimulus is mediated by the endocannabionid system, involving glutamatergic 
neurons but not stress hormone signalling.
In the second set of experiments, we challenged the view that the fear level at the end of an 
exposure session (within-session extinction) is the indicator for the strenght of between-ses-
sion extinction. By comparing different exposure approaches, we were able to show that the 
decline of fear during exposures did not predict formation of between-session extinction, nor 
was it a prerequisite. Multiple short and unpredictable exposures to the stimuli were most ef-
fective in producing between-session extinction, compared to a permanent exposure. Start-
ing from our results obtained in the first set of experiments we further demonstrated that the 
endocannabinoid system is essential for within-session extinction but not for between-session 
extinction. The dissociation of within-session and between-session extinction allowed us to 
pin down the basolateral amygdala, the cingulate cortex and the dentate gyrus as possible 
centers of relearning by measuring c-Fos immunoreactivity in various brain areas.
Even after successful completion of extinction training subjects are prone to relapse. Re-
consolidation, elicited by re-exposure, was recently identified as a phase where the  original 
fear memory becomes vulnerable again to selective modifications. Therefore in the third set 
of experiments, we tried to interfere with reconsolidation in order to achieve a long lasting 
decrease in conditioned fear. By inhibition of intracerebral activity of PKC, within- and be-
tween-session extinction were facilitated and moreover renewal and spontanous recovery, as 
a control for relapse, were abolished. We showed for the first time that reconsolidation can 
be manipulated without having any negative influences on memory consolidation during ex-
tinction training. By means of c-Fos immunohistochemistry we were able to identifiy the cin-
7gulate cortex as a candidate region to mediate reconsolidation processes.
In summary this study demonstrates for the first time that endocannabinoid signalling at 
glutamatergic neurons in the forebrain is essential for within-session extinction but also in-
dependent of CRH signalling and corticosterone secretion. Second, within-session and be-
tween-session extinction can be dissociated at the behavioural, anatomical and molecular 
level. Third, by blocking reconsolidation, the conditioned fear memory trace can be degraded 
during extinction, thus resulting in a lasting decrease of fear. These findings challenge a num-
ber of facts, which have been taken for granted in current psychotherapy practice. We hope 
that this thesis will contribute to develop new therapeutic approaches for the treatment of 
phobias or trauma-related anxiety disorders.
82. Synopsis
2.1. Introduction 
 
2.1.1. Phobias and trauma related anxiety disorders and exposure therapy in 
humans
Anxiety disorders were descibed as early as the fourth century B.C. in the “corpus hippo-
craticum”, but their impact on society was not fully appreciated until some decades ago. The 
first specialists in psychiatry were mainly concerned with the description and classification 
of psychotic disorders. As a result the development of the field of anxiety disorders was left 
to specialists in internal medicine and neurology, like S. Freud (Pichot, 1994). Since then psy-
chologists and psychiatrists have tried with pharmacological and phsychological treatments 
to change undesired emotional memories.
Excessive fear is a hallmark of a variety of disabling anxiety disorders . However, most 
treatments only eliminate fearful responses, leaving the original fear memory intact. Once 
aquired, emotional memory is very long lasting. From an evolutionary point of view, it is ex-
tremely important to never forget the most significant events in life. In order to survive, in-
dividuals require mechanisms that avert threat. To this end, defensive responses, including 
fear, evovled. Fear is an emotional state which can appear without previous experience of 
threat and whose shape can be altered by learning to produce new patterns of defensive be-
haviour. This, however, can also be harmful and maladaptive, such as in some trauma victims 
who suffer from dreadful memories.
The development of reliable diagnostic criteria set the stage for a critical appraisal of the 
magnitude of the problem of anxiety disorders. According to statistical evaluations over 80 
million women and men of all ages in the EU are estimated to suffer from  this mental dis-
order. Considering ICD-10 and DSM-IV criterion there is clear evidence that more than one 
third of the adult European population is or has been affected, or 50% of the population, 
if lifetime risk is considered (Olesen and Leonardi, 2003; Andlin-Sobocki et al, 2005). The 
enourmous suffering that can be associated with theses disorders  is self evident. Typically 
school, academic career, social environment, somatic health and also social life are heavily 
impaired. Panic disorders, or phobias can emerge already in childhood and adolescence. They 
are also a major cause for premature mortality, either caused by suicide or by the effects of 
complications arising from associated risk factors. 
The most effective strategies for phobias and trauma related anxiety disorders include expo-
sure based interventions and pharmacotherapy (Norton and Price, 2007). It has been gener-
ally assumed that combining two effective interventions should result in greater gains than 
only one. Surprisingly some clinical trails showed that patients who received a combination 
of cognitive behavioural therapy and anxiolytics showed a loss of efficacy once the medica-
tion was discontinued (Otto et al., 1995; Gelder et al., 1998; Barlow et al., 2000) A specific 
reason for this not yet known. Discontinuation of medication may alter the internal state 
which may in turn interfere with learning that took place during a different internal state. 
9Or it is possible that the fear reduction is attributed to the fear expression, based on phar-
macological disinhibition, rather than on a learning effect. It is also possible that the anx-
iolytic effect of pharmacotherapy inhibits the full activation of the fear structure, leading 
to a suppression of emotion processing of the feared stimuli. Thus the combined treatment 
may not outperform cognitive behavioural therapy alone, but may even place patients at rel-
atively greater risk of relapse. However, it has been shown that pharmacotherapy aimed not 
at treating symptoms of anxiety but instead at improving the relearning that takes place in 
exposure therapy might acutally improve the treatment effectiveness. When D-Cycloserine, 
a partial NMDA agonist, is combined with exposure the beneficial effect, of exposure, is sig-
nificantly enhanced. This has already been shown for a variety of psychiatric diseases like 
phobia and other anxiety disorders (Ressler et al, 2004; Hofmann et al, 2006; Kushner et al, 
2007).
The effect of D-Cycloserine was not first reported in humans, but rather in a rodent model of 
exinction of conditioned fear (Walker et al, 2002). Recently it was also shown in rodents that 
fear can be reduced for a long period of time not only by pharmacological means but also 
by modification of behavioural protocols (Monfils et al, 2009). The strategies of this model 
were readily transferred to human subjects and the findings proved consistent (Schiller et al, 
2010). This examples show that results obtained in rodent models for conditioned fear and 
extinction prove applicable also in  human populations.
2.1.2. Extinction as explicit model of exposure therapy in rodents 
I.P. Pavlov (1849-1936) was the first to show the learned association between a uncondition-
ied stimulus (US) and a conditioned stimulus (CS) that leads to a reproducable conditioned 
response (CR). Therefore this procedure is called “Pavlovian Conditioning”, or classical con-
ditioning (Pavlov, 1927). In classical conditioning paradigms a subject has no control over 
presentations of the US by its own behaviour and the stimulus-stimulus association (CS-US) 
is explicit and fixed.  After repeated exposure to the CS without US the CR diminishes over 
time. This decrease is consistent across paradigms and species and is referred to as extinction. 
It was shown that extinction is not due to forgetting of the original US-CS association.Ex-
tinction rather is an active learning process that requires repeated training to develop. Some-
times extinction is also described as an unlearning process dependent on violation of the CS-
US expectancy (Rescorla, 1988).
However this unlearning view has been challenged repeatedly during the last years. It was 
shown that extinction is not simply forgetting the original association, because, first the CR 
does not dissapear over time without reexposure to the non-reinforced CS. Second, the ex-
pression of the extinguished fear vanishes over time and the CR reappears (spontanous re-
covery) after a appropriate time without reexposure (Robbins, 1990). The fact that extinc-
tion is context dependent (renewal) is a third argument against unlearning . If an association 
is aquired in context A and extinction is performed in context B animals will only show re-
duced fear responses in context B but not in context A when retested(Bouton and Bolles, 
1979). Both, renewal and spontaneous recovery demonstrate that the original CS-US associ-
ation stays intact during extinction procedures. Because of these findings a new theory was 
developed that extinction is a form of new learning that opposes the expression of the CR 
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(Bouton, 1993). During extinction a second, inhibitory, association of CS- no US is formed 
and strengthened, which directly acts in parallel to the conditioned association which pre-
dicts the US after the CS onset. This inhibitory learning theory is able to explain most of the 
basic behavioural features of extinction to this day (Ehrlich et al., 2009).
However some authors claim that not only associative processes are involved in extinction 
(Kamprath and Wotjak, 2006). Extinction of conditioned fear seems to include habituation 
(Harris, 1941; McSweeney and Swindell, 2002). When a stimulus of the same characteristics 
is presented in a uniform way for a long time, responsivness of a subject to the stimulus will 
be decreased. Also the strength of the US during acquisition influences the intensitiy of fear 
displayed during later exposures. Therefore extinction obviously involves many different fac-
tors which could influence the short-term and the long-term development of behaviour dur-
ing repeated exposures towards the conditioned stimuli.
In rodents fear is defined as a cessation of all bodily movements except for respiraton (freez-
ing) increase in the amplitude of acoustic starte responses, changes in blood pressure, ultra-
sonic distress calls, place avoidance, or other behavioural changes in presence of the CS. In 
most studies during conditioning, a tone is paired with a mild foot shock. For reexposures 
animals are transferred in a defined context and, for practical reasons, freezing to the CS is 
quantified. 
Defensive behaviours consist basically of three categories relevant for the entire animal king-
dom, including humans: freezing, fleeing and fighting (Eilam, 2006). These defense reactions 
reflect the integrated final output of different brain systems. In order to trace processes in-
volved in the control of defensive responses, it is necessary to standardize the  fear response 
and to control its releasing stimuli. For this, a simple response elicited by a single stimulus, 
such as a certain odour or noise, is best fitting. Recently it was suggested that defensive be-
haviour is two dimensional. Defensive reactions can vary dependend on the distance to the 
threat (defensive distance) and the avoidability (defensive direction) (McNaughton and Corr, 
2004). In people suffering from phobias or trauma related anxiety disorders there seem to be 
a shift in balance between defensive reactions. They tend to show inadequate reactions in re-
altion to the defensive distance or defensive reaction. For example, people already show pan-
ic-like reactions while the fear eliciting stimulus is still far off. During exposure therapy the 
defensive distance is deliberately minimized to evoke a maximum emotional reaction. There-
fore, by regulation of the defensive distance certain behavioural defensive responses can be 
evoked, for example, freezing in rodents. Since inhibitory interactions between brain struc-
tures mediating defensive behaviour can rapidly switch as the threatening situation varies 
(Gonzalez et al., 2003) a fixed, controlled environment has to be provided throughout extinc-
tion experiments. This allows reproducability of a distinct defense behaviour and compara-
ble involvement of certain brain regions. 
2.1.3. The endocannabionid system and fear expression
In recent years the endocannabionid system (ECS) has emerged as a intrinsic neuromod-
ulatory system involved in a magnitude of physiological processes, including the regula-
tion of fear responses. The system consists of two receptors, endocannabionid receptor 
type 1 (CB1) and type 2 (CB2), (Matsuda et al., 1990; Munro et al., 1993), endocannabi-
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noids, namely N-arachidonoylethanolamide (AEA) and 2-Arachidonylglycerol (2-AG) (Dev-
ane et al., 1992; Mechoulam et al., 1995) and associated enzymatic machinery for synthe-
sis (enzymes of the lipid metabolism) and degradation (FAAH: fatty acid amino hydrolase, 
MGL:monoacylglycerol lipase) of endocannabionids (McKinney and Cravatt, 2005; Dinh et 
al., 2002). Both, CB1 and CB2 receptors, were found following the identification of the main 
psychoactive compound of marijuana, delta9-tetrahydrocannabinol (THC) (Mechoulam and 
Gaoni, 1965), which bind the receptors directly. The CB2 receptor is almost exclusively ex-
pressed on cells of the immune system and only in restricted areas in the central nervous sys-
tem (Skaper et al, 1996; Van Sickle et al, 2005). In contrast, the CB1 receptor is among the 
most abudant expressed G protein-coupled receptors in the central nervous system (Herken-
ham et al., 1990; Howlett et al.,1999;  Freund et al., 2003; Piomelli, 2003). At subcellular lev-
els most CB1-receptors are found on axon terminals of GABAergic and glutamatergic  syn-
Figure 1: Endocannabionid mediated short-term plasticity
Endocannabinoid production can be incuded by two processes: (1) post synaptic depolariza-
tion induces Ca2+ via voltage-gated calcium channels (VGCC); (2) brief excessive stimulation 
or mGluR activation by endocannabinoids (e.g. 2-AG) will activate presynaptic CB1 receptors, 
leading to a short term depression of neurotransmitter release. (Adapted from Lutz and Marsi-
cano, 2006)
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apses (Monory et al., 2006) and their activation leads to presynaptic inhibition of transmitter 
release (Schlicker and Kathmann, 2001) by hyperpolarisation of the neuron. Endocannabi-
noids are synthesised „on demand“ in particular conditions, such as during anxiogenic or 
fearful situations (Wotjak, 2005; Marsicano and Lutz, 2006) and excert their effect on trans-
mitter release in a retrograde fashion (Figure 1).
Clearance of endocannabinoids from the extracellular matrix is rapidly accomplished via a 
high affinity, selective and temperature dependent process, which suggests a carrier mediated 
transport by which diffusion is faciliated. Also considering the fast kinetics of endocannabi-
onid synthesis, release and degradation, there seems to be a closely drawn time and location 
dependency of effects (Piomelli, 2003). This could explain why exogenous cannabionid ap-
plication could not mirror endocannabinoid effects in some cases, because in this case spatial 
and temporal connections are violated (Marsicano and Lutz, 2006).
It has been shown that the endocannabionid system, and more specifically the CB1 receptor 
is not only involved in neuroendocrine responses (Steiner et al.., 2008), but also in processing 
of acquired fear, including fear conditioning and extinction. In 2002 Marsicano, Wotjak et al. 
showed, in a rodent model, that the exinction of conditioned fear is controlled by the endo-
cannabionid system. In this study, mice lacking the CB1 receptor were able to show normal 
acquisition but failed to show reduction of fear during several reexposure sessions. This was 
also reproducable by blocking the function of the receptor pharmacologically. Later on it was 
shown that this effect depends mainly on non-associative factors (habituation) in extinction 
(Kamprath et al., 2006). These findings have some striking similarities when linking them to 
pathological fear and anxiety in humans (LeDoux, 2000). As mentioned before, fear regula-
tion during exposure to a feared stimulus is essential for adequate behaviour and is often dis-
turbed in humans with anxiety disorders. Several experiments showed that, in rodents, fear 
adapation could be accelerated by additional CB1 stimulation (Chhatwal et al., 2005.; Pam-
plona et al., 2006; Varvel et al., 2007). Also CB1 activation seems to have differential effects 
on distinct phases of memory consolidation, dependent on the pharmacons used for CB1 ac-
tivation (Lin et al., 2006).
Marijuana and its derviates have been used in humans for medicinal purpose for quite a long 
time. The shown results, obtained in rodents, suggest that they may have also therapeutic 
potential in anxiety related disorders. The endocannabinoid system could represent a target 
for diseases with inappropriate fear adaptaion (Haller et al., 2004a + 2004b). A promising 
compound could be cannabidiol, a non psychotropic constituent of cannabis. It has already 
been shown to reduce anxiety in humans (Zuardi et al., 1982; Williamson and Evans, 2000). 
However, cannabidol signalling does not involve CB1-receptors (Moreira et al., 2006) but it 
seems to mediate its effects by opioid receptors (Kathmann et al., 2006). 
The endocannabionid system has shown to be a promising target for new therapeutics augu-
menting treatment for anxiety disorders but still many things are unknown.
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2.1.4. Fear expression and Stress
The CB1 receptor is expressed in various regions of the brain (Herkenham et al., 1990) and 
plays a important role not only in fear expression, but also in locomotion, pain perception, 
feeding, and more (Porter and Felder, 2001). In addition, the endogeneous cannabinoids af-
fect the production of various hormones, including growth hormones, thyroid hormones and 
glucocorticoids (Brown and Dobs, 2002) and also play a role in the control of the hypothal-
amo-pituitary-adrenocortical (HPA) axis (Weidenfeld et al., 1994; Pagotto et al., 2001, Di et 
al., 2003; Barna et al, 2004; Steiner et al, 2008). At the level of the HPA axis endocannabi-
onids seem to interact with the corticotropin-releasing hormone (CRH) system (Wenger et 
al., 1997) and a functional interaction between these two systems could be shown in multi-
ple studies (Corchero et al., 1999; Cota et al., 2003; Haller et al., 2004; Hermann and Lutz, 
2005). Given the key role of CRH and the HPA axis in the regulation of stress and anxiety 
related responses (DeKloet, 2003; Muller et al., 2003), there may be a functional relationship 
between the effects of cannabinoids on anxiety and the HPA axis.
CRH is a potent mediator of endocrine, autonomic and immune responses to stress (Holsboer 
and Barden, 1996) and has been implicated in the modulation of a wide range of different 
types of behaviour, including arousal and anxiety-related behaviour (De Souza, 1995). CRH 
activates two distinct types of G protein-coupled receptors, CRHR1 and CRHR2, which are 
present with different expression pattern in the brain. CRHR1 is expressed at different levels 
in neocortical areas, the hippocampus, basolateral amygdala, ventral tegmental area, pon-
tine gray, lateral dorsal tegmentum, pedunculopontine tegmental nucleus and anterior pitu-
itary, which is not a part of the brain (Potter et al., 1994; Sanchez et al., 1999; Van Pett et al., 
2000). In some areas it is differentially coexpressed with the CB1 receptor, in particular, in 
olfactory regions,  some cortical and limbic areas and some hypothalamic and thalamic nu-
clei (Hermann and Lutz, 2004). CRHR2 is found in the lateral septum, the bed nucleus of the 
stria terminalis, medial and cortical nuclei of the amygdala, dorsal raphe and in the nucleus 
of the solitary tract. CRH is a high affinity ligand for CRHR1m but binds CRHR2 with a 
much lower affinity, where the primary ligand is urocortin. CRH receptors are linkked to dif-
ferent intracellular singalling pathways, which differ between brain regions, thus resulting in 
a neuroanatomically signaling specifity of CRH receptors (Artz and Holsboer, 2006).
Stress involves a large number of neuronal circuits, including the prefrontal cortex, the hip-
pocampus, the amygdala, the septum and the hypothalamus. Activation of these circuits by 
stress results among other things, in the release of corticotropin-releasing hormone. CRH 
is released from parvocellular neurons of the paraventricular nucleus of the hypothalamus 
(PVN) (Swanson and Simmons, 1989) into portal vessels and activates the HPA axis by trig-
gering the immediate release of adrenocorticotropic hormon (ACTH) from the anterior pitu-
itary (DeSouza, 1995). This in turn stimulates the cortex of the adrenal gland to synthesize 
and release glucocorticoids. 
Studies in rodents have shown anxiogenic-like effects of CRH administration (Dunn and 
Berridge, 1990). Moreover, brain structures with high expression of CRHR1, such as the 
amygdala, the BNST, prefrontal cortex and the periaqueductal grey have been strongly im-
plicated in mediating emotional processes such as fear and panic (Coplan and Lydiard, 1998). 
It was shown that intracerebroventriculary (ICV) administration of CRH increased condi-
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tioned fear to a conditioned stimulus (Radulovic et al., 1999). In addition, another study 
showed that injection of a CRH receptor agonist directly into the basolateral amygdala pro-
duced a very potent anxiogenic-like effect (Sajdyk et al., 1999). This suggests that CRH may 
induce fear, or anxiety, related behaviour in rodents by activation of CRH1.
Across species THC and CB1 receptor agonists and antagonists stimulate corticostrone secre-
tion, irrespective of sex or route of administration. It has been proposed that the HPA axis 
stimulating actions of CB1 receptor agonists and antagonists are centrally mediated and re-
sult in the activation of neurons in the paraventricular nucleus (PVN) of the hypothalamus. 
Observations imply a model for glucocorticoid-mediated fast feedback-regulation in these 
neurons, which is based on endocannabionid signalling (Di et al., 2003). Increased corticos-
terone levels feek back onto membrane bound and G-protein-coupled glucocorticoid recep-
tors in PVN neurons. Thereby local synthesis of anandamide and 2-AG is triggered, which 
travel retrogradely and bind to presynaptic CB1 receptors on glutamateric afferences of the 
PVN and result in a reduction of glutamate release.. This results in a reduced activation of 
the CRH-containing PVN neurons and, in consequence, in a re-setting of the HPA axis fol-
lowing stressor exposure (for review see Steiner and Wotjak, 2008).
These studies lead to the assumption, that, because of the close relationship to the endocan-
nabionid system, CRH mediated effects could play a role in fear adaption during exposure to 
a conditioned stimulus. By investigating this relationship potential new targets for phama-
cological augumentation of exposure therapy could come apparent.
2.1.5. Second messengers in cell to cell signalling
Overall there are two types of receptors in the cell membrane neurotransmitters can bind 
to. The first group are the ionotropic receptors. The receptor is an integral part of the same 
macromolecule that forms the ion-channel it regulates. Upon binding the neurotransmitter 
the receptor undergoes a conformational change that results in the opening of the channel. 
These types of receptors have a very short reaction time and therefore serve as the first in-
stance of cell signaling. The second group of receptors are the metabotropic receptors, where 
the receptor and the effector functions are carried out by different proteins. This receptor 
type consists of different subgroups, including the G-protein coupled receptors and the ty-
rosin-kinase receptors. The G-protein coupled receptors are coupled to a guanine nucleotide 
binding protein (G-protein) (Figure2). The intracellular tyrosin kinase domaine autophos-
phorylates itself after extracelluar ligand binding, allowing it to bind and also phosphorylate 
other intracellular proteins, including other kinases. The response kinetics of metabotropic 
receptors are much slower and due to their indirect action pose the second instance of cell 
signaling, because of the indirect action.
The best known targets for G-proteins are the cyclic adenosine monophosphate (cAMP) and 
the phosphoinositol (IP) second messenger pathways. In the cAMP pathway a stimulatory 
G-protein (Gs) phosphorylates the adenylyl cyclase which in turn catalyses the conversion 
of ATP to cAMP. cAMP in turn activates the cAMP-dependent protein kinase (PKA). In 
the inositol pathway a receptor associated Gq protein activates the phospho lipase C (PLC), 
which cleaves phosphatidylinositol-1,4,5-bisphosphate (PIP2) into diacylglycerol (DAG) and 
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inositol-1,4,5-triphosphate (IP3). The DAG activates the protein kinase C (PKC), whereas 
IP3 mobilized intracellular Ca2+ stores by docking to a receptor in the endoplasmatic re-
ticulum. PKC is synergisticly activated by DAG and Ca2+. Both of these second messengers 
control downstream processes which leads to long term changes of synaptic excitability, like 
transcription and translation. Moreover they can influence signal input to neurons by trans-
location, internalisation or enhanced recruitment of receptors to the synaptic cleft. So it is 
not surprising that both messenger systems are also critically involved in learning and mem-
ory processes (for detailed information see Cammorota et al., 2005; Dash et al., 2007). Tak-
en together, the second messenger systems integrate a vast amount of receptor signals and 
translate them straightforward into long and short term adaptive  neuronal changes.
The above mentioned CB 1 belongs to the metabotropic group. Interestinly, not a stimula-
tory,  but an inhibitory G-protein (Gi) (Howlett et al., 1999) is coupled to the receptor and, 
by that, it seems to downregulate synaptic transmitter release. Activation of the receptor 
leads to the inhibition of adenylyl caclase, activation of extracellular signal regulated kinas-
es 1 and 2, increased activation of inwardly rectifying K+ channels (GIRK) and inhibition 
of voltage-gated calcium channels (Howlett et al., 2002). Some details about interactions be-
tween the endocannabinoid system and the PKC are also known. Data shows that protein ki-
nase C is activated by cannabinoids, like THC, cannabinol and cannabidiol, in vitro (Hillard 
and Auchampach, 1993). Also arachidonic acid, which is the precursor of Anandamide and 
2-AG, interacts with PKC and seems to increase its activity (Nishizaki et al., 1999), which 
leads to facilitation of hippocampal synaptic transmission. Moreover PKC seems to disrupt 
endocannabionid signaling by direct phosphorylation of the CB1 receptor in the third intra-
cellular loop, which is important for G-coupled signalling (Garcia et al., 1998). 
Figure 2: Selected modulatory neurotransmitters and their receptors that couple to either Gi, 
Gs, or Gq
Receptors that are necessary for working memory initiate second messenger pathways. G-
Proteins have distinct effects on intracellular signalling. Gs enhances cAMP concentrations via 
the adenylylcyclase (AC) resulting in protein kinase A (PKA) activation. Gi reduces cAMP levels. 
Gq proteins couple to phospho-lipase C (PLC), causing increases in intracellular diacylglycerol 
(DAG) and inositol triphosphate (IP3). (Adapted from Dash et al., 2007)
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Combined findings suggest that PKC activity could be involved in a regulatory feedback 
mechanism for the endocannabionid system. It is possible that influencing this regulatory 
mechanism and not the the endocannabionid system directly could lead to new insights in 
extinction, or ,respective, exposure therapy.
2.1.6. Consolidation and Reconsolidation
Memory consolidation is the process by which the long-term memory of an item stabilizes 
and becomes resistant to certain sources of interference, such as distracting stimuli, electric 
shocks or metabolic inhibitors (McGaugh, 2000; Dudai). The question of whether is any item 
in long term memory consolidation occurs just once, or wether memories reconsolidate each 
time anew after retrieval, (Dudai, 2004), has potential practical implications. Evidence in-
dicates that after activation, items in long term memory may regain transient sensitivity to 
consolidation blockers (Nader, 2000; Taubenfeld et al, 2001; Eisenberg et al., 2003). The sta-
bility of a memory in general, has high relevance in the attempt to understand and develop 
treaments for certain pathologies that involve persistent activation of undesired memories.
A well-established type of consolidation blocker used in memory consolidation experiments 
are the protein synthesis inhibitors (Davis and Squire, 1984). But none of these agents is 
completely specific (Kyriakis et al., 1994). In recent years, a lot of attempts have been made 
to identify molecular mechanisms of reconsolidation by inhibitors of cellular targets rang-
ing from receptors and channels to intracellular signal transduction cascades, transcription 
factors and immediate early genes (for review see Dudai and Eisenberg, 2004). There are also 
studies which indentify differences between consolidation and reconsolidation, for example, 
there is a dissociation between the roles of BDNF and Zif268 (Lee et al., 2004). It is not yet 
known whether such differences are fundamental or emerge only in specific memory types 
or protocols. Although the pharmacological and molecular data suggests that consolidation 
and reconsolidation share many mechanistic components, there are, for sure, also differences.
By finding targets which are selectively involved in reconsolidation processes but not consoli-
dation, a specific fear memory knock-down should be possible.
2.1.7. Aims 
The aim of this thesis was to identify new approaches to exposure therapy. 
Our working hypotheses have been as follows:
(1) Endocannabinoids excert their acute effect on fear extinction via glutamatergic
  transmission
(2) Corticosterone secrection plays an important, though indirect, role in fear extinction
  by stimulating endocannabinoid signalling
(3) A permanent stimulus exposition during training is not efficient in building up
  between session extinction 
(4) Acute fear relief is  not the prerequisite for relearning of the tone-shock associationt
(5) Inhibition of PKC activity promotes fear extinction by inhibition of reconsolidation
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2.2 Discussion
In the first part of the thesis we were able to show, that endocannabionids mediate acute 
fear adapation independently of the CRH system (manuscript 1).We sensitized mice defi-
cient for the endocannabinoid 1 receptor (CB1 -/-) and their wildtype littermates (CB1+/+) 
to various footshock intensities and were able to show that only with high intensities the 
CB1-/- mice showed a sustained fear response to the tone. Moreover, when testing condition-
al mutants with a deletion of the CB1 receptor either in principal neurons of the forebrain 
(CaMK-CB1-/-) or in cortical glutamateric neurons (Glu-CB1-/-), all display a similar pheno-
type compared to CB1-/- animals. This indicates, that glutamateric transmission, under en-
docannabionid control, is essential for acute fear adaptation after traumatic experiences. By 
these findings we were able to verify our working hypothesis 1.
To find out, wether this inability for fear adaptation, after high intensity shocks, is relat-
ed to the experienced stress we blocked the CB1 receptor pharmacologically by rimonabant 
(SR141716) in mice deficient for the corticotropin releasing hormone receptor type 1 (CRHR1 
-/-) and type 2 (CRHR2 -/-) and their wildtype littermates. All genotypes showed a sustained 
fear response. These results suggests that the fear alleviating effect of the endocannabio-
nid system is not connected to the CRH system. Moreover ,because CRHR1-/- mutants are 
known to be severely impaired in stress induced corticosterone secretion, our observations 
imply that corticosterone is dispensable for CB1-mediated acute fear adaptation. This clearly 
asks for rejection of our second working hypothesis.
In the second part (manuscript 2) we wanted to investigate the involvement of acute fear 
adapation in formation of long-term extinction memory. Therefore, we conditioned mice to 
a tone and afterwards assigned them to three different exposure paradigms. The paradigms 
were identical in total exposure duration but differed in the duration of a single stimulus du-
ration and the time between stimuli intervals. All groups showed the same acute fear adap-
ation on the first day after conditioning. On the following days, the groups exposed to the 
ten single tones with constant and variable inter-stimulus intervals showed memory buildup. 
Furthermore, the group with variable intervals proved most effective, compared to the group 
exposed to a single permanent tone, which did not show any long term extinction memory 
over all days. Additionally, the experiment showed that acute fear reduction during exposure 
(within session extinction) does not  predict extinction memory buildup (between session ex-
tinction), neither is it a prerequisit, as we showed in extinction of remote fear memory. These 
findings proofed our third and fourth working hypothesis.
To further strenghten the point we exposed CB1-/- and their wildtype littermates to the per-
manent and variable interval protocols. In a parallel experiment we injected wildtype ani-
mals with a CB1 receptor antagonist, or vehicle. The groups with impaired endocannabionid 
signalling showed impaired acute fear adapation (within-session extinction) but developed 
between session extinction memory. We also implemented further exposures on day 10 and 
day 40 to test animals for the consitency of the extinction memory. The groups with memo-
ry buildup on d3 showed a similar level of fear on d10 and spontaneous recovery, which is a 
reapperance of the fear reaction towards the tone, on day 40. C-Fos immunoreactivity was 
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upregulated in several brain areas after rimonabant injection and exposure, but only in the 
basolateral amygdala, the cingulate cortex and the dentate gyrus the activation showed to be 
consistent, irrespective of pharmacological treatment, after exposure to the variable interval 
protocol. These areas are likely to mediate between session extinction. Taken together the re-
sults show that within and between session extinction are dissociable processes. As a second-
ary finding, we showed that endocannabinoids are mostly dispensable for long term memory 
buildup and seem to only play a role in acute fear adapation (within-session extinction).
As our fifth working hypothesis we stated that PKC activity is essential for reconsolidation.
In manuscript 3 we inhibited protein kinase C activity during exposure to asses possible ef-
fects on extinction learning. On d1 and d2, we saw, after injection, increased fear adapation 
during exposure to the permanent tone, but more interestingly we also saw increased be-
tween-session extinction, compared to vehicle group. The phenotype is consistent up to d10 
and spontanous recovery on d40 was abolished. To ensure extinction specifity we performed 
several control experiments. Inhibition of PKC activity alone on d1 and d2 was not sufficient 
to decrease initial freezing or fear adapation during reexposure on d3. Also, shortened expo-
sure combined with pharmacon treatment did not show any effects on freezing levels. Inhib-
iting  PKC activity during conditioning or during preexposure to the tone was not able to 
produce any differences, compared to vehicle treated animals. This showed that the initially 
observed phenotye was specific for extinction and was also dependent on exposure length.
Extinction learning consists of two distinct phases, which describe sensitive time windows, 
in which learning is prone to external manipulations, namely consolidation and reconsoli-
dation. We injected animals again on d1 and d2 but exposed them to the variable interval 
protocol, which we showed produces between session extionction. From d1 to d10 all groups 
showed similar within and between session extinction. This shows that memory consolida-
tion during extinction learning is not disturbed by PKC inhibition. However on d40 spon-
taneous recovery was abloished in the inhibitor injected group. Inhibition of PKC activity 
impaired reconsolidation processes, but did not influence consolidation. Thus, our fifth work-
ing hypothesis proofed valid. Therefore, as a secondary finding we can state that consoli-
dation and reconsolidation are independent processes. By c-Fos immunohistochemistry we 
were able to identify the cingulate cortex as a potential player in reconsolidation processes.
Since all results are already discussed in detail in the attached manuscripts, a more general 
discussion will give insights into the scientific impact of the obtained results in the field of 
extinction and exposure therapy in a translational perspective.
2.2.1. Terminology for extinction progression
A lot of different research groups work with models of extinction in order to reveal basic 
learning mechanism. This asks for a common standard of nomenclature. However, this is 
not the case and similar processes are described by different terms (Myers and Davis, 2007). 
We encountered several problems in terms of description of our findings with the given no-
menclature. The following description bases on real behavioural data (Plendl and Wotjak, 
2010). In principle, we ask for a dissociation of within- (1) and between-session extinction 
(2) (Figure 3A). Within-session extinction describes the decrease of freezing over the course 
of one session and is identical to the term fear relief, which is often used in the human field. 
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Between-session extinction describes the fear decrease between two sessions and is the com-
parison of the initial fear levels of two different sessions (Figure 3B). It  expresses the active 
learning component in extinction and, therefore, can also be referred to as the actual relearn-
ing event. The relapse of fear after a long period of non-exposure is called spontaneous re-
covery (3) and can also be described by the comparison of initial freezing levels between two 
distant sessions, for expample d10 and d40. It is wrong to compare the end of a session with 
the beginning of a new session as a measurement of spontaneous recovery, because of the 
shown dissociation between within- and between-session.
A good quantification can be achieved, if fear responses are evaluated in time bins. In our 
case we split the total 200 seconds duration in ten 20 second bins, defined by the length of 
the CS during conditioning. But in other experiments, with longer exposure durations, single 
bin length could be adjusted accordingly. Also, between-session extinction and spontaneous 
recovery can be presented as changes in initial fear levels (Figure 3 B). We believe that this 
detailed mode of analysis helps to better visualize extinction progess. A common way to vi-
sualize freezing data is to show freezing scores averaged over the whole session duration, but 
this way of analysis could produce false positives. To demonstrate this we condensed the be-
havioural data of Figure 3 A into a single data point per day, which is the average of freezing 
over the whole sesion (Figure 3 C). By looking at the figure, a decline in freezing in the perma-
nent tone group seems obvious, however by looking at the detailed analysis in Figure 1 A, or 
the initial freezing levels in Figure 3 B, one could see that actual there is no between session 
extinction in the pt group. Thus, this decline in overall freezing must be dependent on other 
factors. When plotting within session extinction of d1 and d10 of the pt group together (Fig-
ure 3 D), it becomes clear that the decline of freezing in C is caused by an accelerated with-
in-session extinction. Because of the uniformity of the stimulus, this is most likely based on 
non-associative processes (Kamprath and Wotjak, 2004) and, therefore, we term this fear de-
cline between-session habituation (4) (Figure 3C).
Figure 3: Extinction Terminology
The graphs introduce a new terminology of fear extinction on basis of the behavioural perfor-
mance of wild-type controls exposed to a permanent tone (pt; A-D) or to repeated tones at vari-
able intervals (vi; A-C) during extinction training. Development of freezing is either described 
in 20s bins (A,B,D) or averaged over the whole exposure time of 200s (C). (1) Within-session ex-
tinction or acute fear relief (A); (2) between-session extinction or relearning (A,B); (3) spontane-
ous recovery or relapse (A,B); (4) between-session habiutation (C,D) (Adapted from Plendl and 
Wotjak, 2010)
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With this proposed terminology the progress of extinction data could be expressed in detail 
and comparability between different data sets should be increased. Moreover, reanalysing 
already existing data might give new insights into extinction and could possibly reveal new 
exciting results out of experiments already finished some time ago. Additionally it has to be 
mentioned that this nomenclature is meant for behavioural paraidgms, which are designed 
to elicit freezing as the main behavioural response. This is especially important if the freez-
ing level during the first 20 seconds of tone exposure is used as a measurement of between-
session extinction.
For example, initially CB1 -/- mice were described as being impaired in long-term extinction 
(Marsicano et al., 2002). Later it was shown that this impairment is dependent on the lack 
of acute fear adapation (Kamprath et al., 2006). Our study now showed that mice deficient 
for the endocannabionid system are able to develope between-session extinction, despite the 
lack of within-session extinction. This now clearly defines the role of the endocannabinoid 
system in acute fear adaptation and shows that more detailed analysis can lead to more and 
better conclusions.
2.2.2. Implications for exposure therapy
A major aim of our work was to provide hints to improve behavioural therapy. In the sec-
ond manuscript we concentrated on exposure pardigms and therefore created three different 
protocols, which relied on already reported findings. We decided to confront a massed ver-
sus a spaced approach and also to introduce variablity into the spaced protocol. This led to 
the permanent (pt) paradigm, as a massed approach, the constant interval paradigm (ci), as 
a spaced, and the variable interval, as a spaced approach with a temporal unpredictability 
factor (vi). For all paradigms we used a fixed context, which was different in many features 
from the conditioning context. Our results showed that most efficient in producing relearning 
was the variable interval protocol (vi). This means that not the total amout of exposure time 
leads to buildup of long term exintction memory but actually the amount of experience en-
counters with the feared stimuli. In the permanent paradigm (pt) there is only one encounter 
per session, whereas in the constant (ci) and variable interval (vi) paradigms this happens ten 
times in one session. It seems that each encounter strengthens the inhibitory memory trace, 
which finally leads to a long lasting fear decay. Additionally temporal unpredictability seems 
to increase the inhibitory tendency.
Currently in psychotherapy a more or less massed approach is used to treat patients. Pho-
bia patients are confronted with the feared stimuli for a certain duration of time in order to 
(i) evoke maximum level of fear and (ii) to reach a maximal decay of fear. On first sight, this 
procedure is not as time intensive as a spaced approach and therefore maybe more conve-
nient for the patient. Moreover it could be less stressfull for the patient because there is only 
one maximum inital fear response per session and a fast onset of habituation effects, which 
leads to fear decay. In a spaced protocol the patient is repeatedly confronted with the feared 
stimuli and moreover there are consolidation periods inbetween, which can raise stress levels 
significantly, because of the ecxptected reexposure. Taken together, spaced exposure training 
could raise stress levels for patients significantly. However we could show in our animal model 
of extinction (manuscript 2), spaced exposures at variable intervals seem to be most effective 
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in eliciting long term changes in fear expression levels.
In order to minimize the expenditure of therapy time, which overall lowers stress levels, 
pharmacotherapy could be added for augumentation of the beneficial outcome of exposure 
therapy.
2.2.3. Pharmacological augumentation of exposure therapy
Up to now, in most behavioural studies, only single receptors, like the CB1 receptor, were in-
vestigated in connection with extinction phenotypes. This can be a promising approach to 
model certain kinds of diseases, where a “specific defect- specific disease” relationship is giv-
en, or where single symptomps of a disease are modeled. But especially psychatric diseases, 
like phobias, or trauma related anxiety disorders, can have multifactorial causes (Smoller et 
al., 2008).
It is impossible to target specific receptors in specific brain regions for therapeutical aims in 
humans. Generally, most pharmactherapies are applied systemically and therefore already 
the blood brain barrier is a big obstacle and can require huge efforts in pharmaceutical design 
to be overcome. If the drug passes the barrier all targeted receptors throughout the brain are 
affected. Neuronal trafficking is limited in time and space to minimize signal to noise ratio. 
Therefore, manipulations on this level seem to have low success rates in multifactorial diseas-
es, because of low specifity and possible high side effects. For expample, the selective CB1-
receptor angatonist rimonabant, which was also used in our work to impair fear adapation, 
was used in humans to treat unwanted side effects, during antidepressant treatment. It was 
effective but also led to increased suicidality as a side effect, which resulted in non-approval 
of the drug on all markets.
Anterograde transmitted signals are integrated in post-synaptic potenial changes and mo-
lecular cascades in the target neurons. Major molecular cascades in signal transduction are 
the second messengers which serve as coincidence detectors, upon which various extracellu-
lar signals are integrated into one condition. The phosphorylation status of the protein ki-
nase C is determined by extracelluar ligand binding to receptors and also by the intracellular 
calcium level, which is also largely determined by receptor gated channels. It could be pos-
sible that multifactorial phenotypes are reflected by changes in second messenger activity 
levels. There are already some evidences obtained in animal models that the regulation of 
second messenger cascades does play a role in anxiety and depression . Fluoxetine, a pharma-
con which is widely used for therapy in depression or post traumatic stress syndrom, seems 
to target beta-arrestin (David et al, 2009), which regulates the activity of G-protein coupled 
receptors (Lohse et al, 1990).
In our experiments blockade of the CB1 receptors in impairment of within-session extinction 
but not of between-session extinction. Decreasing the actvitiy of protein kinase C had a dual 
effect on fear. It not only seemed to decrease within-session extinction, but also decreased be-
tween-session extinction and, most importantly, prevented relapse. From this point of view, 
downstream effector systems seem to be promising targets for long term modulation of be-
havioural phenotypes. But one also have to keep in mind, that most drugs discovered so far, 
which modulate memory processes can not be readily adminsistred to humans (Monfils et al., 
2009) and specifity can not be ensured.
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2.2.4. The fear extinction brain matrix
The amygdala is one of the key brain structures for consolidation of memory (LeDoux, 
2000; Maren, 2001; Fanselow and Poulos, 2005). Moreover, it modulates fear related learn-
ing in other brain structures, such as the cortex and the hippocampus (McGaugh, 2004). The 
amygdala consists of several anatomically and functionally distinct nuclei including the lat-
eral (LA) and basolateral (BLA) nuclei and the central nucleus (CEA), which can be divided 
into the lateral (CEI) and a medial (CEm) part. In addition, there are clusters of GABAergic 
interneurons (ITC) surrounding the BLA, which are thought to gate interactions between 
the BLA and the CEA. Corresponding to current models, the LA serves as a sensoric inter-
face (McDonald, 1998), as it receives sensory information from the thalamus and cortex. The 
CEm serves as the principal output station (LeDoux, 1988) and its projections contact dif-
ferent structures in the brainstem and in the hypothalamus. In addition amygdala nuclei are 
connected to many cortical and subcortical brain structures, which participate in generating 
behaviourally relevant outputs (Pitkänen et al., 2000). This suggests that information can 
be processed by intrinsic mechanisms as well as by interactions with other brain structures 
to integrate sensory inputs, generate fear response outputs and modulate fear responses, de-
pending on environmental influences (Sah et al., 2003). There is accumulating evidence indi-
cating that local inhibitory circuits in the amygdala contribute or even mediate important 
aspects of fear conditioning and extinction. Systemic, or local treatments can interfere with 
the acquisition or expression of conditioned fear (Harris and Westbrook, 1999 and 2001), 
but also, they can improve learning and retrieval (Tang, 2003). Also, inhibitory neurons in 
the amygdala are major targets of neuromodulatory systems, which may allow adjustment 
of networks according to environmental conditions and the behavioural state (Muller et al., 
2007; Pinard 2008). 
We were able to verify the crucial role of the amygdala in fear adapation and extinction of 
fear memory. In our second study we showed that an increase of c-Fos activity in the basolat-
eral amygdala accompanied extinction learning. Moreover changes were observed in the cin-
gulate cortex and the dentate gyrus. However, in our third study, inhibition of PKC activity 
upon reactivation of fear memory failed to elicit consistent activity changes in the amygdala, 
but rather in the cingulate cortex. 
The process by which labile new memories are stabilized into long lasting memories is refered 
to as consolidation. In principle, three different ideas about consolidation are discussed.  One 
argues that memory representations are gradually transferred over time among brain areas 
(McClelland et al, 1995; Knowlton and Fanselow, 1998). The second view relates to the way 
in which the memory strength is modulated in a given brain area as a result of activity from 
other areas or influences like hormones (Cahill and McGaugh, 1995). These two hypotheses 
focus largely on interactions between brain areas. The third idea relies on cellular and molec-
ular events, that convert labile memory traces into stable, long term ones (DeZazzo and Tul-
ly, 1995; Bailey et al., 1996). These theories are not entirely different but put their emphasis 
on different processes. 
In fear conditioning, inactivation of the amygdala, by infusion of GABA agonists, before 
acquisition impaires memory formation (Wilensky et al., 1999) and disruption of protein 
synthesis prevents the formation of long-term memory for fear conditioning (Schafe and 
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LeDoux, 2000). These observations indicate that the amygdala is important for the consoli-
dation of this kind of memory. 
We have shown in our third manuscript, that inhibition of PKC activity impaires reconsoli-
dation, which leads to long term fear decay. Because of abolished renewal and spontaneous 
recovery, it shares similarities with amnesia. Amnesia for a particular experienced can follow 
after certain intrusions, such as electronconvulsive shocks (Duncan, 1949), inhibition of pro-
tein synthesis (Davis and Squire, 1984) or brain injury, but only if they occur shortly after 
the learning event (McGaugh, 1966). Another possibility is, when a newly learned associa-
tion for one task is immediately followed by another association for the same task, the first 
one could be compromised (retroactive interference). For this process temporal proximity is 
essential.
Over the years it has been shown the same manipulations can also lead to memory loss af-
ter reactivation of the memory. Moreover, it seems that the same temporal restrictions apply. 
Electro-convulsive stimulation and new learning can affect reactivated memory only imme-
diatly after but not after a certain period of time has passed (Dawson and McGaugh, 1969; 
Sara, 2000, Nader et al, 2000). Therefore, reactivated and new memories seem to exist in sim-
ilar states during certain periods of time.
A recent publication dealt with memory representation in brain circuitry after reactivation 
(Winocur et al., 2009) and showed that after acquisition memories go through a labile phase 
in which they are vulnerable to disruption. At a later timepoint more brain regions seem to 
be integrated into memory consolidation, which leads to a stable long term memory. This in-
tegrated memory trace is less vulnerable to modifications. But when the stable memory is 
reactivated by a reminder, it undergoes reconsoliation and again enters a labile, vulnerable 
phase. This phase is again time restricted.
Taken together, these findings tell us, that consolidation and reconsolidation might be very 
similar processes. Our results implicate, that consolidation and reconsolidation may share 
the same brain circuitry, but the core areas and molecular recuritment could be different. In 
our second manuscript, we showed that mainly the basolateral amygdala, the dentate gyrus 
and the cingulate cortex are invoveld in consolidation, by increased activation. In our third 
manuscript it was shown that, the cingulate cortex seem to be the area to mediate reconsoli-
dation processes. By inhibition of PKC activity we were able to decrease the activity in this 
area and therefore, impair reconsolidation  processes. During consolidation of the fear mem-
ory this blockade of activity had no effect on acquisition, or latent inhibition.
Our study can still not definitetly answer the question of how consolidation and reconsoli-
dation are organised. At least we can state, that consolidation of extinction memory and re-
consolidation, in our hands, are controlled by different brain regions and second messenger 
systems.
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2.3. Outlook
Out of new results, new questions arise.
Are second messengers a new therapeutical target for psychatric disorders? Currently phar-
macotherapies, which indirectly modulate the PKC activity level are mainly used in depres-
sive patients, such as Lithium Chloride and Valproic acid (Zarate and Manji, 2009 ;Bowden 
et al., 2010). Our findings implicate that these pharmacons could find a new use in augumen-
tation of exposure therapy. Animal experiments in this direction should be conducted to find 
out if this is a valid approach. Positive findings could results in a major gain for patients un-
dergoing exposure treatment.
We have shown that PKC activity mediates memory reconsolodation. However, the details 
of the mechanism and the molecular targets of PKC involved, are not yet known. To find out 
more, screens should be performed for regulation of other proteins by PKC. Because we iden-
tified the cingulate cortex as a possible brain region to regulate reconsolidation, this struc-
ture should be addressed in detail. 
Furthermore, other second messengers and their role in memory regulation could be interest-
ing. PKA is known to play a major role in memory consolidation and acquisition (Arsten et 
al., 2005) and currently also comes in focus as a therapeutic target for memory disorders. But 
tyrosine kinases have not been addressed yet and could pose an interesting target. It could 
be that second messengers play differential roles during memory phases, for example PKA 
in consolidation, PKC in reconsolidation and tyrosine kinases mediate another phase, not yet 
known.
This brings us to the question, what is really neccessary to produce a long term change in a 
fear memory. Do patients really have to undergo exposure sessions or is it enough to induce 
reconsolidation right from the start? Are there early and late phases of reconsolidation? 
Which phase is most prone to modifications? Do patients have to be conscious at all? Recon-
solidation could be an automatic process, which triggers intrusive memories, and does not 
necessarily involve the awareness of the patient. 
Revelation could come while sleeping.
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Recent evidence showed that the endocannabinoid sys-
tem plays an important role in the behavioral adaptation
of stress and fear responses. In this study, we chose
a behavioral paradigm that includes criteria of both fear
and stress responses to assess whether the involvement
of endocannabinoids in these two processes rely on
common mechanisms. To this end, we delivered a foot-
shock and measured the fear response to a subsequently
presented novel tone stimulus. First, we exposed differ-
ent groups of cannabinoid receptor type 1 (CB1)-deficient
mice (CB1
2/2) and their wild-type littermates (CB1
1/1) to
footshocks of different intensities. Only application of an
intense footshock resulted in a sustained fear response
to the tone in CB1
2/2. Using the intense protocol, we
next investigated whether endocannabinoids mediate
their effects via an interplay with corticotropin-releasing
hormone (CRH) signaling. Pharmacological blockade of
CB1 receptors by rimonabant in mice deficient for the
CRH receptor type 1 (CRHR12/2) or type 2 (CRHR22/2),
and in respective wild-type littermates, resulted in a sus-
tained fear response in all genotypes. This suggests that
CRH is not involved in the fear-alleviating effects of CB1.
As CRHR12/2 are known to be severely impaired in
stress-induced corticosterone secretion, our observation
also implicates that corticosterone is dispensable for
CB1-mediated acute fear adaptation. Instead, conditional
mutants with a specific deletion of CB1 in principal neurons
of the forebrain (CaMK-CB1
2/2), or in cortical glutamatergic
neurons (Glu-CB1
2/2), showed a similar phenotype as
CB1
2/2, thus indicating that endocannabinoid-controlled
glutamatergic transmission plays an essential role in acute
fear adaptation.
Keywords: CB1, corticosterone, CRF, CRH, endocannabi-
noids, extinction, HPA axis, rimonabant, SR141716, stress
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Endocannabinoids are fatty acid derivatives that exert their
effects on emotional and motivational behavior, cognition,
pain perception and neuroprotection primarily via central
cannabinoid receptor type 1 (CB1) (Piomelli 2003). They are
synthesized and released on demand from postsynaptic sites
and act as retrograde messengers at presynaptic terminals
where they activate CB1 and thereby suppress neurotrans-
mitter release (Wilson & Nicoll 2002). CB1 is expressed by
different neuronal subpopulations including GABAergic and
glutamatergic neurons (Marsicano & Lutz 1999). Among other
functions, CB1 was shown to mediate extinction of condi-
tioned fear (Chhatwal et al. 2005; Marsicano et al. 2002;
Suzuki et al. 2004), whereby it seems to be involved in
habituation-like processes (Kamprath et al. 2006). The latter
observation strikingly resembles the findings of Hillard and co-
workers (Patel et al. 2005), who showed that endocannabi-
noids mediate habituation to homotypic stressors. Based on
these similarities, we hypothesize that a common mecha-
nism underlies endocannabinoid-mediated fear and stress
adaptation.
Recently, Patel and Hillard (2008) proposed a mechanism
for endocannabinoid-mediated stress habituation, which cen-
trally involves the modulation of glutamatergic signaling.
Upon repeated exposures to restraint stress, which results
in habituation of the behavioral response, levels of the
endocannabinoid 2-arachidonoyl glycerol (2-AG) in cortical
brain regions were found to be increased (Patel et al. 2005;
Rademacher et al. 2008). Cortical glutamate efflux, in con-
trast, was shown to decrease under similar circumstances
(Moghaddam 2002). 2-arachidonoyl glycerol-mediated activa-
tion of CB1 located on glutamatergic terminals might explain
the decrease in glutamate signaling. Thus, it is conceivable
that unrestrained glutamate release may also account for the
sustained fear responses observed in CB1-deficient mice
(Kamprath et al. 2006; Marsicano et al. 2002), particularly if
one considers the importance of glutamatergic transmission
in the regulation of defensive behavioral responses (Millan
2003; Nordquist et al. 2008).
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In addition to glutamate, corticotropin-releasing hormone
(CRH) was described to control behavioral stress coping,
including fear and anxiety, via the hypothalamic–pituitary–
adrenal (HPA) axis and/or via extrahypothalamic brain areas by
activating CRH receptor type 1 (CRHR1) and type 2 (CRHR2)
(for reviews, see Bale & Vale 2004; Keck et al. 2005; Steckler &
Holsboer 1999). Interestingly, both CRH (Cota et al. 2003,
2007) and CRHR1 (Hermann & Lutz 2005) colocalize with CB1
in hypothalamic and extrahypothalamic brain areas, suggest-
ing that CB1 may inhibit CRH signaling, accounting for the
exaggerated fear responses observed in CB1-deficient mice
(Marsicano et al. 2002). In addition to CB1 influencing CRH
signaling, corticosterone itself can potently activate the
endocannabinoid system in the hypothalamus (Di et al.
2003). This, in turn, inhibits glutamatergic afferences, thereby
constraining HPA-axis activity and further corticosterone
release.
Taken together, likely candidates in a common mechanism
for endocannabinoid-mediated adaptation of fear and stress
responses include glutamatergic transmission, CRH and the
HPA axis with the possibility for multiple interdependences.
Noteworthy, the extent of HPA-axis activation is determined
by the intensity of the stressor (Armario et al. 1986; Hennessy &
Levine 1978; Hennessy et al. 1979), which parallels recent
findings in the endocannabinoid system, namely that the
anxiolytic-like actions of endocannabinoids and their effects
on stress-coping behavior seem to depend on the aversive-
ness of the test situation (Haller et al. 2004; Naidu et al. 2007).
However, it remains to be shown that endocannabinoid-
mediated fear adaptation is characterized by a similar
dependency.
In the present study, we investigated the impact of the
aversiveness of the previously encountered stressful experi-
ence on the involvement of endocannabinoids in fear adap-
tation. To this end, we applied inescapable footshocks of
different intensities to different groups of CB1-null mutant
mice and their wild-type littermates and measured their fear
responses to a tone on the following day. The most effective
protocol was then applied to rimonabant-treated CRHR1-
deficient (Timpl et al. 1998) and CRHR2-deficient (Coste
et al. 2000) mice to test the hypothesis that an interplay of
the endocannabinoid system and CRH signaling is responsi-
ble for the sustained fear response observed in animals with
impaired CB1 signaling. Finally, we investigated which neu-
ronal subpopulation expressing CB1 is involved in the pre-
viously observed phenotype by means of conditional mutants
lacking CB1 expression either in principal neurons of the
forebrain (CaMK-CB1; Marsicano et al. 2003) or in cortical
glutamatergic neurons (Glu-CB1; Monory et al. 2006). The
specific deletion of CB1 in CaMK-CB1
/ affects, among
others, glutamatergic and GABAergic projection neurons of
cortical and subcortical brain structures, including the hypo-
thalamus (Marsicano et al. 2003). Consequently, in the fore-
brain of these mice, expression of CB1 is largely constricted
to GABAergic interneurons. Glu-CB1
/, in contrast, affects
a much lower number of neurons because these mice lack
CB1 specifically in cortical glutamatergic neurons, thus main-
taining CB1 expression in subcortical brain structures (includ-
ing the hypothalamus; Monory et al. 2006). If CB1, indeed,
mediates its fear-alleviating effects via restriction of cortical
glutamate release, the phenotype of the two conditional
mutant lines should resemble that observed in conventional
CB1 knockouts with germ-line deletion of the CB1 gene.
Materials and methods
All experiments were approved by the Committee on Animal Health
and Care of the State of Bavaria (Regierung von Oberbayern,
Germany) and performed in strict compliance with the European
community recommendations for the care and use of laboratory
animals.
Animals
Male mice at the age of 8–14 weeks were used in all experiments.
All mutant mice and their respective wild-type littermate controls
were generated and genotyped as described previously (CB1
/,
n ¼ 61 and CB1þ/þ, n ¼ 68: Marsicano et al. 2002; CaMK-CB1/,
n ¼ 13 and CaMK-CB1þ/þ, n ¼ 14: Marsicano et al. 2003; Glu-CB1/,
n ¼ 14 and Glu-CB1þ/þ, n ¼ 10: Monory et al. 2006; CRHR1/,
n ¼ 14 and CRHR1þ/þ, n ¼ 14: Timpl et al. 1998; CRHR2/, n ¼ 14
and CRHR2þ/þ, n ¼ 18: Coste et al. 2000). All CB1-mutant mice (CB1,
CaMK-CB1 and Glu-CB1 mice) were backcrossed to C57BL/6NCrl for
six generations. The CRHR1/ and CRHR1þ/þ mice were originally
generated by Timpl et al. using 129/Ola and CD1 mouse strains (see
Timpl et al. 1998 for detailed description) and not backcrossed to any
mouse strain but maintained by means of heterozygous breeding
pairs. The CRHR2/ and CRHR2þ/þ mice (courtesy of M. Stenzel-
Poore, Oregon Health & Science University, Portland, OR, USA) were
backcrossed to C57BL/6J for four generations. All conventional
mutant mouse lines (CB1
//CB1
þ/þ; CRHR1//CRHR1þ/þ and
CRHR2//CRHR2þ/þ) were maintained by heterozygous breeding
pairs. Only homozygous male offspring were used for the experi-
ments. Conditional mutant mouse lines (CaMK-CB1
þ/þ/CaMK-CB1
/
and Glu-CB1
þ/þ/Glu-CB1
/) were maintained by breeding pairs con-
sisting of Cre()xCB1fl/fl (i.e. wild-type) mothers and Cre(þ)xCB1fl/fl
(i.e. knockout) fathers to avoid effects of the genetic modulation on
maternal care. For the experiments, the male offspring were taken
from different breeding pairs with respect to closely matching birth
dates (the maximum variation among birth dates was 6 weeks).
Because most litters do not contain equal numbers of male mutant
and wild-type offspring, most breeding pairs did not contribute equal
numbers of mutant and wild-type animals to the experimental groups.
However, care was taken that at least one wild-type littermate was
tested together with each mutant mouse and vice versa.
All animals were reared at the animal facilities of the Max Planck
Institute of Psychiatry, Munich, Germany. Animals were single
housed under an inverse 12 h:12 h light–dark cycle (lights off:
0900 h) with food and water ad libitum for at least 14 days before
starting the experiments.
Experimental procedures
Experiments were performed on two consecutive days with applica-
tion of the footshock (sensitization) on day 1 and exposure to the tone
on day 2. Rimonabant was applied subcutaneously (s.c.) 45 min
before tone presentation on day 2. All experiments were performed
during the animals’ active phase between 0930 and 1700 h.
Sensitization
Mice were placed into the shock context where they received
a single inescapable footshock of 2 seconds duration essentially as
previously described (Kamprath & Wotjak 2004). Shock sensitization
at the individual pain threshold (PT) was achieved by manually raising
the shock intensity until the animal showed the first signs of pain and
discomfort (jumping and/or vocalization). The respective current
intensity was maintained for 2 seconds, before the current was
switched off. Naı¨ve (non-shocked) controls were not placed into the
shock context.
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Tone presentation
On the day following footshock sensitization, mice were placed into
a new ‘test context’ that differed from the shock context in various
aspects, including shape, odor, illumination and bedding (see
Kamprath & Wotjak 2004 for details). After 3 min, a tone of 9 kHz
and 80 dB was presented for 3 min.
Experiment 1: Interrelation between CB1-deficiency,
footshock intensity and subsequent fear response to
a tone
CB1/ and CB1
þ/þ were randomly assigned to five experimental
groups, which differed in the intensity of the stress sensitization
procedure as follows: the first group remained non-shocked (0 mA;
CB1
/: n ¼ 10; CB1þ/þ: n ¼ 11), the second group received a foot-
shock a t the i nd i v i dua l PT (CB 1
/: n ¼ 15 ; CB 1þ/þ:
n ¼ 10), the third group received a footshock with a current intensity
of 0.5 mA (CB1
/: n ¼ 8; CB1þ/þ: n ¼ 9), the fourth group received a
footshock with a current intensity of 0.7 mA (CB1
/: n ¼ 20; CB1þ/þ:
n ¼ 26) and the fifth group received a footshock with a current
intensity of 1.5 mA (CB1
/: n ¼ 8; CB1þ/þ: n ¼ 12). The extent of
sensitization was assessed by measuring the freezing response to
a 3-min tone at the next day. Note that the groups of mice that
received a 0.7-mA shock are identical to those published before
(Kamprath et al. 2006).
Experiment 2: Interplay between CB1 and CRHR1 in fear
adaptation following footshock sensitization
The CRHR1/ and their wild-type littermates received a footshock of
1.5 mA (which proved to be the most effective in experiment 1), and
the extent of sensitization was assessed by measuring the freezing
response to a 3-min tone on the next day. Half of the CRHR1/ mice
(n ¼ 7) and their wild-type littermates (n ¼ 7) were treated with
rimonabant (10 mg/kg, s.c.) 45 min prior to the tone presentation,
and the other half (CRHR1/: n ¼ 7; CRHR1þ/þ: n ¼ 7) were treated
with vehicle.
Experiment 3: Interplay between CB1 and CRHR2 in fear
adaptation following footshock sensitization
The CRHR2/ and their wild-type littermates received a footshock of
1.5 mA, and the extent of sensitization was assessed by measuring
the freezing response to a 3-min tone on the next day. Half of the
CRHR2/ mice (n ¼ 7) and their wild-type littermates (n ¼ 9) were
treated with rimonabant (10 mg/kg, s.c.) 45 min prior to the tone
presentation, and the other half (CRHR2/: n ¼ 7; CRHR2þ/þ: n ¼ 9)
were treated with vehicle.
Experiment 4: Role of CB1 expressed by principal neurons
of the forebrain in fear adaptation following footshock
sensitization
CaMK-CB1
/ and their wild-type littermates received a footshock of
1.5 mA, and the extent of sensitization was assessed by measuring
the freezing response to a 3-min tone on the next day.
Experiment 5: Role of CB1 expressed by cortical
glutamatergic neurons in fear adaptation following
footshock sensitization
Glu-CB1
/ and their wild-type littermates received a footshock of
1.5 mA, and the extent of sensitization was assessed by measuring
the freezing response to a 3-min tone on the next day.
Behavioral analysis
The behavioral response to the tone was videotaped. Fear was
assessed off-line by a trained observer who scored the freezing
response of the animals unaware of the genotype or treatment condition
as described before (Kamprath & Wotjak 2004). Freezing was defined as
the absence of all movements except for those related to respiration.
Drug treatment
Rimonabant [SR141716; N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-
dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide; kindly provided
by NIMH Chemical Synthesis and Drug Supply Program (Rinaldi-
Carmona et al. 1994)] was dissolved in vehicle solution (one drop
Tween-80 in 3 ml 2.5% dimethylsulfoxide in saline) to a final concen-
tration of 10 mg/kg and injected s.c. at 20 ml per kg body weight under
light isoflurane anesthesia 45 min prior to behavioral testing. The
subcutaneous route of drug administration was chosen on basis of
previous experiments (Kamprath et al. 2006; Marsicano et al. 2002). The
time-point of injection (45 min prior to behavioral testing) was based on
the study of Petitet et al. (1999), who showed that rimonabant elicits its
strongest effects up to 60 min after administration independent of the
route of administration. The interval between injection and behavioral
testing was maximized within the given temporal range to avoid
possible effects of the injection stress on the outcome of the behavioral
testing. The dose of rimonabant (10 mg/kg) was chosen on basis of
a dose–response experiment in C57BL/6J mice, the background strain
of CRHR2 mutant mice (Figure S1) and because of its higher efficiency
in terms of promoting stress-induced corticosterone secretion in
C57BL/6N mice (Steiner et al. 2008a).
Data analysis and statistics
For analysis, the total time of tone presentation was subdivided into
20-second bins with one data point representing one interval. For
every interval, the duration of freezing was expressed as a percentage
of the total time of the interval (‘freezing time’ per interval/total
interval time 100). Data were analyzed by two-way or three-way
analysis of variance (ANOVA) for repeated measurements as indicated
in the text using STATISTICA 5.0 (StatSoft Inc., Tulsa, OK, USA) or
GRAPHPAD PRISM 5.0 (GraphPad Software Inc., San Diego, CA, USA).
Newman–Keuls test was used as the post hoc test if appropriate.
Data are presented as mean  SEM. Statistical significance was
accepted if P < 0.05.
Results
Experiment 1: Fear-alleviating effects of
endocannabinoids depend on the intensity of the
previously encountered footshock
To investigate whether CB1 mediates the adaptation of the
fear response in an aversiveness-dependent manner, we
applied inescapable footshocks of different intensities to
different groups of CB1-deficient mice (CB1
/) and their
wild-type littermates (CB1
þ/þ). One day later, we assessed
the behavioral responses of all groups of mice to the same
novel stimulus, an 80-dB tone. Both CB1
/ and CB1
þ/þ
showed an increase in freezing to the tone with increasing
shock intensities (Fig. 1; statistics not shown). Significant
genotype differences became evident only after application of
a footshock of 0.7 mA (genotype: F1,44 ¼ 9.7, P ¼ 0.003;
genotype  interval: F8,352 ¼ 3.5, P < 0.001; Fig. 1) or
1.5 mA (genotype: F1,18 ¼ 10.6, P ¼ 0.004; genotype 
interval: F8,144 ¼ 3.6, P < 0.001; Fig. 1) but not in the case
of lower footshock intensities (statistics not shown). A
significant decrease in the development of the freezing
response over the 3-min tone presentation was observed in
all groups of CB1
þ/þ which experienced a footshock, while
CB1
/ shocked with 1.5 mA failed to reach significance
(F8,56 ¼ 1.8, P ¼ 0.09, one-way ANOVA), in contrast to their
wild-type littermates (F8,88 ¼ 6.5, P < 0.0001). Thus, the
strongest footshock protocol (1.5 mA) yielded the most
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pronounced genotype effects. Non-shocked mice showed
very little freezing (0 mA, statistics not shown; Fig. 1).
Experiment 2: Interplay between CB1 and CRHR1 in
fear adaptation following footshock sensitization
As both the endocannabinoid system and the CRH signaling
play important roles in the adaptation to stressful events, and
recent literature suggests an interplay between both sys-
tems, our next aim was to investigate whether CRHR1 is
involved in CB1-mediated fear adaptation following sensitiza-
tion with high footshock intensities. To this end, we used
CRHR1/, which were shown, among others, to be strongly
impaired in stress-induced corticotropin (ACTH) and cortico-
sterone responses (Timpl et al. 1998). Thus, pharmacological
blockade of CB1 in CRHR1
/ would be expected to be
ineffective if CB1-mediated acute fear adaptation depends
on CRHR1 signaling or on stress-induced ACTH or cortico-
sterone release. Based on the previous experiment, a foot-
shock of 1.5 mA was applied to CRHR1þ/þ and CRHR1/.
On the next day, the freezing response of the animals to the
tone was measured. Forty-five minutes prior to tone expo-
sure, half of the animals for each genotype were treated with
the CB1-antagonist rimonabant (10 mg/kg, s.c.) and the other
half with vehicle. A three-way ANOVA (drug, genotype and
interval) showed that, similar to a genetic CB1 deficiency, the
CB1 antagonist rimonabant caused an increased freezing
response (drug: F1,24 ¼ 8.8, P ¼ 0.007), which was indepen-
dent of the genotype (drug  genotype: F1,24 ¼ 0.002, P ¼
0.96; Fig. 2). A significant drug  interval interaction
(F8,192 ¼ 2.4, P ¼ 0.016) points to a delayed fear adaptation
in rimonabant-treated animals that was independent of the
genotype (drug  interval  genotype: F8,192 ¼ 1.56, P ¼
0.14). Interestingly, CRHR1/, in general, showed a stronger
freezing response than their wild-type littermates (genotype:
F8,48 ¼ 18.8, P ¼ 0.0002), irrespective of the treatment (drug
 genotype: F1,24 ¼ 0.002, P ¼ 0.96).
Experiment 3: Interplay between CB1 and CRHR2 in
fear adaptation following footshock sensitization
Data of experiment 2 indicate that acute effects of CB1 on fear
adaptation occur independent of CRHR1 signaling and stress-
induced corticosterone release. However, the effects of CRH
on stress coping depend also on another receptor, CRHR2 (for
review, see Bale & Vale 2004). Thus, the various ligands of the
CRH family might interact with the endocannabinoid system
during the acute fear response via CRHR2. Therefore, we
applied a footshock of 1.5 mA to CRHR2þ/þ and CRHR2/
and measured their freezing response to the tone on the next
day 45 min after treatment with rimonabant (10 mg/kg, s.c.) or
vehicle. A three-way ANOVA (drug, interval and genotype)
showed that, similar to CRHR1/, the CB1 antagonist rimo-
nabant caused an increased freezing response (drug:
Figure 1: Fear-alleviating effects of endocannabinoids depend on the intensity of the aversive encounter. The freezing
responses of both CB1
/ (j) and CB1
þ/þ (u) to a 3-min tone presented 24 h after application of an inescapable footshock showed
a clear dependency on the intensity of the previously encountered footshock. CB1 deficiency caused a sustained freezing response after
application of an inescapable footshock of high-shock intensities (0.7 and 1.5 mA) only. No significant differences could be detected in
the freezing responses of naı¨ve mice (0 mA) and of mice that were shocked either at the individual PT (approximately 0.25 mA) or with
0.5 mA. Data are displayed in 20-second bins. *P < 0.05, ***P < 0.001 (for sample sizes, see Materials and methods). Note that the
groups of mice that received a 0.7-mA shock are identical to those published in Kamprath et al. (2006) (copyright 2006 by the Society for
Neuroscience).
Figure 2: The CB1-antagonist rimonabant caused increased
freezing in both CRHR11/1 and CRHR12/2. CRHR1þ/þ (d, s)
and CRHR1/ (j, u) received a footshock of 1.5 mA, followed
by exposure to a 3-min tone 24 h later. Before tone presentation,
mice were treated either with 10 mg/kg, s.c. rimonabant (d,j) or
with vehicle (s, u). Data are displayed in 20-second bins.
*P < 0.05 (for sample sizes, see Materials and methods).
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F1,28 ¼ 26.6, P < 0.0001), which was independent of the
genotype (drug  genotype: F1,28 ¼ 0.86, P ¼ 0.36; drug 
interval  genotype: F8,224 ¼ 0.94, P ¼ 0.48; Fig. 3). Note-
worthy, no significant genotype differences could be detected
between CRHR2þ/þ and CRHR2/ (genotype: F1,28 ¼ 0.57,
P ¼ 0.46; genotype  interval: F8,224 ¼ 0.95, P ¼ 0.48).
Experiment 4: CB1 deficiency in principal forebrain
neurons leads to impaired fear adaptation following
footshock sensitization
To investigate which neuronal subpopulation expressing CB1 is
mediating fear adaptation following footshock stress, we next
tested CaMK-CB1
/, a conditional mutant line, which lacks
CB1 expression in principal neurons of the forebrain (Marsicano
et al. 2003). The specific CB1 deletion in these mice includes,
among others, CB1 expressed by glutamatergic neurons of
cortical and subcortical brain structures and by GABAergic
projection neurons. Based on the results of experiment 1, we
subjected these animals to the strongest protocol, that is
application of a footshock of 1.5 mA and measured the freezing
response to a tone 24 h later. CaMK-CB1
/ showed a signi-
ficant difference in the freezing response compared with their
wild-type littermate controls (genotype: F1,25 ¼ 4.5, P ¼ 0.04;
genotype  interval: F8,200 ¼ 3.9, P < 0.001; Fig. 4). This dif-
ference was characterized by the feature that CaMK-CB1
/
were not able to decrease their freezing response over the
course of the 3-min tone presentation (F8,96 ¼ 1.2, P ¼ 0.29;
one-way ANOVA), in contrast to their wild-type littermates
(F8,104 ¼ 6.5, P < 0.0001).
Experiment 5: CB1 deficiency in cortical glutamatergic
neurons leads to impaired fear adaptation following
footshock sensitization
In CaMK-CB1
/, CB1 expression in the forebrain is restricted
to GABAergic interneurons, that is a relatively high number of
neurons lack CB1 expression (Monory et al. 2006, 2007). To
further narrow down which neuronal subpopulation express-
ing CB1 mediates fear adaptation following footshock stress,
we tested Glu-CB1
/, another conditional mutant line, which
lacks CB1 expression specifically in cortical glutamatergic
neurons (Monory et al. 2006). In contrast to CaMK-CB1
/,
the specific CB1 deletion in Glu-CB1
/ does not include CB1
expressed by hypothalamic neurons. Similarly to CB1
/ and
CaMK-CB1
/, Glu-CB1
/ showed a stronger freezing
response to the tone than their wild-type littermate controls
(genotype: F1,22 ¼ 4.3, P ¼ 0.049; Fig. 5). Although we failed
to observe a significant genotype  interval interaction
(F8,176 ¼ 1.2, P ¼ 0.30), one-way ANOVAs performed
Figure 3: The CB1-antagonist rimonabant caused increased
freezing in both CRHR21/1 and CRHR22/2. CRHR2þ/þ (d, s)
and CRHR2/ (j, u) received a footshock of 1.5 mA, followed
by exposure to a 3-min tone 24 h later. Before tone presentation,
mice were treated either with 10 mg/kg, s.c. rimonabant (d, j)
or with vehicle (s, u). Data are displayed in 20-second bins.
***P < 0.001 (for sample sizes, see Materials and methods).
Figure 4: Sustained freezing responses in CaMK-CB1
2/2.
CaMK-CB1
/ (d) and CaMK-CB1
þ/þ (s) received a footshock of
1.5 mA, followed by exposure to a 3-min tone 24 h later. Data are
displayed in 20-second bins. *P < 0.05, **P < 0.005, ***P <
0.001 (for sample sizes, see Materials and methods).
Figure 5: Sustained freezing responses in Glu-CB1
2/2. Glu-
CB1
/ (d) and Glu-CB1
þ/þ (s) received a footshock of 1.5 mA,
followed by exposure to a 3-min tone 24 h later. Data are
displayed in 20-second bins. *P < 0.05 (for sample sizes, see
Materials and methods).
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separately per genotype showed that Glu-CB1
/
(F8,104 ¼ 1.5, P ¼ 0.17), unlike their wild-type littermates
(one-way ANOVA: F8,72 ¼ 2.9, P ¼ 0.007), were not able to
significantly decrease their freezing response over the course
of the 3-min tone presentation.
It is of note that, after application of a 1.5 mA footshock,
none of the CB1-deficient mouse lines (CB1
/, CaMK-CB1
/
and Glu-CB1
/) were able to decrease their freezing re-
sponses over the course of the 3-min tone presentation,
whereas the respective wild-type mice did show a decline in
freezing. Although this decline of the freezing response
appears to be steeper in CB1
þ/þ (wild-types) than in the
wild-types of the conditional mutant lines, CaMK-CB1
þ/þ and
Glu-CB1
þ/þ, these differences between the CB1-deficient
mouse lines failed to reach statistical significance (line:
F2,65 ¼ 2.88, P ¼ 0.063) in a three-way ANOVA (genotype, line
and interval) and might relate to differences in the genetic
background and variations between experiments. In contrast,
the three-way ANOVA showed a significant genotype effect
(F1,65 ¼ 20.5, P < 0.0001) and a significant genotype  inter-
val interaction (F8,520 ¼ 6.8, P < 0.00001), which were inde-
pendent of the line (genotype  line: F2,65 ¼ 1.8, P ¼ 0.17;
genotype  line  interval: F16,520 ¼ 1.3, P ¼ 0.20).
Discussion
The present study shows that CB1 only controls acute fear
adaptation in the aftermath of highly aversive encounters.
This process depends neither on intracerebral CRH signaling
nor on stress-induced activation of the HPA axis, but on CB1-
controlled cortical glutamatergic projections.
To investigate whether the involvement of endocannabi-
noids in fear adaptation depends on the aversiveness of the
situation, we applied inescapable footshocks of different
intensities to different groups of CB1-deficient mice and
studied their fear responses to a subsequently presented
tone. In general, the intensity of the footshock directly
modified the intensity of the fear response to the subse-
quently presented tone in a dose-dependent manner (Fig. 1;
see also Kamprath & Wotjak 2004). However, the fear-
alleviating effects of endocannabinoids only became evident
following the two highest shock intensities (0.7 and 1.5 mA).
These data underscore the general importance of intensity-
response studies for testing the modulation of fear and stress
responses and for evaluating the involvement of different
neuronal systems in these processes. The impairments in
fear adaptation observed in CB1-deficient mice did not relate
to differences in pain perception because differences
between the two genotypes were neither found in the
individual pain thresholds (Marsicano et al. 2002) nor in the
initial fear responses to the subsequently presented tone
(Fig. 1). Moreover, data obtained by pharmacological block-
ade of CB1 before tone presentation (Figs 2 and 3) indicate
that endocannabinoids are acutely involved in the adaptation
of the fear response to the tone following sensitization rather
than in perception of the footshock (Kamprath et al. 2006;
Marsicano et al. 2002).
The finding that the endocannabinoid system mediates fear
adaptation in an aversiveness-dependent manner corrobo-
rates recent findings by Haller et al. (2004), showing that an
anxiogenic-like phenotype of CB1-deficient mice became only
detectable if the illumination of the elevated plus maze (EPM)
was increased and, thus, the aversiveness of the test
situation was maximized. In line with these results, treatment
with the fatty acid amide hydrolase (FAAH) inhibitor URB597,
which blocks degradation of the endocannabinoid ananda-
mide, resulted in anxiolytic-like behavior in the EPM test only
if a distinct strong illumination was used (Naidu et al. 2007) or
if the animals were tested during the light phase of the
circadian cycle (Moreira et al. 2008). Moreover, impairment of
FAAH by pharmacological and genetic means led to increased
active stress-coping behavior in a tail suspension test only if
the aversiveness was increased by a flashlight beam focused
to the animals’ tail in a dimly lit room (Naidu et al. 2007). Our
data extend those findings in that the aversiveness of the test
situation determines endocannabinoid recruitment not only in
terms of anxiety-related and stress-coping behavior but also
in terms of behavioral fear responses.
The findings that endocannabinoid involvement in fear,
anxiety and stress adaptation depends on the aversiveness
of the test situation strikingly resemble the dependency of
HPA-axis activation on the intensity of a stressor (Armario
et al. 1986; Hennessy & Levine 1978; Hennessy et al. 1979).
In the first steps of stress-induced HPA-axis activation, CRH
is released from axon terminals of the hypothalamic para-
ventricular nucleus into the portal blood at the level of the
median eminence, followed by ACTH secretion from the
adenohypophysis, which subsequently triggers the release
of glucocorticoids (i.e. cortisol or corticosterone) from the
adrenal glands. Corticotropin-releasing hormone is also found
in extrahypothalamic brain regions, where it is involved in the
processing of stress responses, anxiety-like behavior and
conditioned fear (Bale & Vale 2004; Keck et al. 2005; Steckler &
Holsboer 1999). Colocalization of CB1 and CRHR1 (Hermann &
Lutz 2005) and of CB1 and CRH (Cota et al. 2003, 2007)
suggest a functional interplay between the two neurotrans-
mitter systems. We therefore assumed that CB1 might
mediate its fear-alleviating effects by restraining CRH signal-
ing within the brain. To address this point, we sensitized
CRHR1/ (Timpl et al. 1998) and CRHR2/ (Coste et al.
2000) with a 1.5-mA footshock and treated the animals with
10 mg/kg rimonabant (s.c.) before exposure to the tone 24 h
later. The rather high dose of rimonabant was chosen on the
basis of a pilot experiment in C57BL6/J mice, the background
strain of the CRHR2 mutant mouse strain (Figure S1). In
addition, a dose of 10 mg/kg was the most efficient in pro-
moting stress-induced corticosterone secretion in C57BL/6N
mice (Steiner et al. 2008a). We cannot entirely rule out that
the high dose of rimonabant might mediate its effects via its
inverse agonist properties. However, the phenotype of CB1-
deficient mice, C57BL/6N mice treated with 3 mg/kg rimo-
nabant (Figure S1; Kamprath et al. 2006) and C57BL/6J mice
treated with 10 mg/kg rimonabant (Figure S1), appears strik-
ingly similar and is most easily explained by an impairment of
CB1 signaling.
Rimonabant treatment led to impaired fear adaptation in
both CRHR1/ (Fig. 2) and CRHR2/ (Fig. 3) and the
respective wild-type controls, thus indicating that the fear-
alleviating effects of endocannabinoids do not involve
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intracerebral CRH systems. Although there is still the possi-
bility for a mutual compensation of CRHR1 and CRHR2
deficiency, this seems to be rather unlikely because
CRHR1/ and CRHR2/ show different phenotypes in
anxiety-related behavior when compared with their respec-
tive wild-type littermates, with CRHR1/ showing decreased
anxiety (Timpl et al. 1998) and different lines of CRHR2-
deficient mice showing either increased anxiety (Bale et al.
2000; Kishimoto et al. 2000) or no changes in anxiety at all
(Coste et al. 2000). Moreover, pharmacological treatment
showed that CRHR1 and CRHR2 seem to exert opposite
effects on auditory fear conditioning (Radulovic et al. 1999).
Recently, Tasker and co-workers suggested a mechanism
for fast glucocorticoid feedback inhibition within the hypo-
thalamus involving endocannabinoid release (Di et al. 2003,
2005b), which might account for endocannabinoid-mediated
stress adaptation. This model requires glucocorticoid secre-
tion to trigger endocannabinoid release within the paraven-
tricular nucleus of the hypothalamus that, in turn, inhibits
glutamatergic afferences to the nucleus and results in CRH
secretion. As a similar interaction between the corticosterone
and the endocannabinoid system has been described for
other parts of the hypothalamus as well (Di et al. 2005a), we
hypothesized that corticosterone regulates endocannabinoid-
controlled fear adaptation in a similar way within the fear
matrix of the brain. However, because CRHR1/, which are
severely impaired in stress-induced corticosterone secretion
(Timpl et al. 1998), still responded to rimonabant, this model
may not apply for acute fear adaptation following footshock
stress.
The CRHR1/ showed an increased freezing response to
the tone following an inescapable footshock compared with
their wild-type littermates, irrespective of the treatment. This
observation was unexpected, taking into consideration the
increased exploratory activity and the reduced anxiety-related
behavior previously reported in these animals (Timpl et al.
1998). The data of the present study suggest that CRHR1 is
differentially involved in fear and anxiety. In contrast to fear-
related paradigms, in which the animal is confronted with an
inescapable stressor, the stressor used in anxiety paradigms
is avoidable, and risk assessment, that is approach of the
stressful situation, is tested. As different neural circuits are
involved in controllable vs. uncontrollable stress (Herry et al.
2007; Kavushansky et al. 2006), CRHR1 might also be
differentially involved. Alternatively, compensatory changes
in other transmitter systems (e.g. upregulation of vasopressin
expression; Muller et al. 2000) might be responsible for the
increased freezing response of CRHR1/. Finally, taking into
consideration that injections of corticosterone at different
learning phases of fear conditioning resulted in a decreased
freezing response (Cai et al. 2006; Skorzewska et al. 2007),
the attenuated HPA-axis response in CRHR1/ with strongly
impaired corticosterone release might lead to an increased
freezing response not only after conditioning but also after
sensitization paradigms. Corticosterone might mediate its
fear-alleviating effects, at least in part, via triggering endo-
cannabinoid release. The phenotype of an increased fear
response following sensitization in vehicle-treated CRHR1/
compared with vehicle-treated CRHR1þ/þ would then relate
to impaired corticosterone-induced endocannabinoid signal-
ing in the mutants (Fig. 2). However, the behavioral differ-
ences between CRHR1/ and CRHR1þ/þ persisted despite
rimonabant treatment (Fig. 2), thus rendering it unlikely that
corticosterone-induced endocannabinoid signaling via CB1 is
crucially involved in the phenotype of CRHR1/.
The question remained as to which transmitter systems are
involved in CB1-controlled fear adaptation during highly aver-
sive encounters. Cannabinoid receptor type 1 was shown to
be expressed widely throughout the brain by different neu-
ronal subpopulations including GABAergic, glutamatergic and
serotonergic neurons (Haring et al. 2007; Marsicano & Kuner
2008; Marsicano & Lutz 1999). To investigate whether
glutamatergic transmission is involved in CB1-mediated fear
adaptation, we applied the strongest footshock protocol,
which was found to yield the strongest effects in CB1
/
(Fig. 1), to CaMK-CB1
/ mutants. These mutants lack CB1
expression in principal forebrain neurons, including glutama-
tergic and GABAergic projection neurons, but sparing CB1
expression in GABAergic interneurons. CaMK-CB1
/
showed a similar impairment of fear adaptation as CB1
/
(Fig. 4). Consequently, an involvement of CB1-expressing
GABAergic interneurons in this behavioral modulation ap-
pears to be rather unlikely. To further narrow down the
neuronal subpopulation involved, Glu-CB1
/ were subjected
to the same protocol with similar effects as observed in CB1
/
and CaMK-CB1
/ (Fig. 5). These results indicate that CB1-
expressing cortical glutamatergic neurons are involved in
endocannabinoid-mediated fear adaptation following inescap-
able footshock stress. According to a mechanism proposed
by Patel and Hillard (2008), endocannabinoid-regulated corti-
cal glutamatergic transmission plays an essential role in the
habituation of repeated exposure to a stressor. Although our
behavioral paradigm did not involve repeated exposures to
the tone, we observed within-session habituation of the
behavioral response. Consequently, the mechanism sug-
gested by Patel and Hillard (2008) might partially account for
acute fear adaptation, that is endocannabinoid-regulated
cortical glutamatergic transmission might play a central role,
whereas increases in 2-AG synthetic capacity via upregulation
of the synthesizing enzymes, which is also part of the
suggested model, may not apply for the current paradigm
of acute fear adaptation, but for the pronounced genotype and
drug effects observed after repeated tone presentations
(Kamprath et al. 2006). Recently, we could show that Glu-
CB1
/ were impaired in behavioral stress coping in a forced
swim test despite unaltered corticosterone secretion (Steiner
et al. 2008b). This supports the notion that endocannabinoid-
mediated control of both behavioral stress and fear responses
may rely on cortical glutamatergic projections, independent of
the activity of the CRH/HPA system.
Taken together, the present study emphasizes the impor-
tance of intensity-response studies for testing the modulation
of fear responses, especially with respect to the endocanna-
binoid system. We showed that CB1 mediates fear adaptation
following inescapable footshocks of high intensity only. Corti-
cotropin-releasing hormone signaling or corticosterone secretion
appears to be dispensable for CB1-mediated fear adaptation,
which, in contrast, critically depends on endocannabinoid-
controlled glutamatergic transmission in cortical brain struc-
tures. Endocannabinoid-mediated behavioral responses to
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stress and fear share similarities in that endocannabinoids are
recruited in aversiveness-dependent manner and especially
involved in habituation-like processes of stress and fear
responses. Moreover, cortical glutamatergic transmission
appears to be modulated by endocannabinoids during stress
and fear habituation, whereby the exact mechanism underly-
ing short-term and long-term habituation still remains to be
determined.
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Dissociation of within- and between-Session Extinction
of Conditioned Fear
Wolfgang Plendl and Carsten T. Wotjak
Max Planck Institute of Psychiatry, 80804 Munich, Germany
Recent findings obtained in patientswith phobias or trauma-related anxiety disorders raise doubts concerning the interrelation between
acute fear relief during an exposure-based therapeutic session and beneficial treatment progress. In amousemodel explicit for exposure
therapy,we challenge the view thatwithin-session fear reduction is the turningpoint for relearning of a stimulus-threat association. Even
thoughwithin-sessionextinctionof auditory-cued fearmemorywas identical forprolongedandspaced tonepresentations, only the latter
caused between-session extinction. Furthermore, spaced tone presentations led to between-session extinction even in the complete
absence of within-session extinction, as observed for remote fear memories and in case of abolished cannabinoid receptor type 1
signaling. Induction of between-session extinction was accompanied by an increase in the number of c-Fos-positive neurons within the
basolateral amygdala, the cingulate cortex, and the dentate gyrus, independent of the level of within-session extinction. Together, our
findings demonstrate that within-session extinction is neither sufficient nor essential for between-session extinction, thus calling for a
reconsideration of current concepts underlying exposure-based therapies.
Introduction
Exposure therapy is an effective treatment of phobias and anxiety
disorders (Marks and Tobena, 1990; Gro¨s and Antony, 2006;
Norton and Price, 2007). Prevailing models interpret the level of
fear throughout exposure trials as an index of beneficial learning.
It is generally assumed that, during an exposure session, a sub-
stantial amount of fear has to be elicited (also called “initial fear
activation”) and subsequently to wane (in a process called
“within-session habituation”) to achieve lasting fear alleviation
(i.e., between-session habituation) (Craske et al., 2008). Recent
findings challenge this view, indicating that performance during
trainingmay not be proportional to therapeutic progress (Pitman et
al.,1996a,b; Craske et al., 2008).
Extinction of conditioned fear is the laboratory analog of ex-
posure therapy in rodents (Rosen and Schulkin, 1998; Myers and
Davis, 2002, 2007; Barad, 2005). Conditioned fear is induced by
pairing a neutral environmental stimulus [conditioned stimlus
(CS), e.g., tone] with an aversive outcome [unconditioned stim-
ulus (US), e.g., electric footshock]. Re-exposure to the CS elicits a
stereotypic, reproducible, and quantifiable behavioral response
(conditioned response, e.g., freezing). During extinction train-
ing, repeated CS presentations in the absence of the US lead to a
decay of the fear response (McSweeney and Swindell, 2002). Ac-
cording to current theories, this decrease does not result from
temporal decay or degradation of the original excitatorymemory
trace but is due to an inhibitory memory trace, which is built up
on re-exposure to the CS in the absence of theUS. This inhibitory
memory trace (CS–no US) competes with and/or suppresses the
original excitatory CS–US memory trace. This notion is sup-
ported by spontaneous recovery of the fear response with the
passage of time after completion of extinction training and its
renewal in an environment different from the extinction context
(Myers and Davis, 2002, 2007; Ehrlich et al., 2009).
We recently demonstrated that the decrease of conditioned
fear over the course of a prolonged tone presentation resembles
habituation-like processes (Kamprath andWotjak, 2004), which
crucially involve cannabinoid receptor type 1 (CB1) signaling
(Kamprath et al., 2006, 2009). Also with this modality, CB1-
deficient mice were strongly impaired, not only in within-session
extinction, but also in between-session extinction of aversive
memories (Marsicano et al., 2002). These phenotypes support the
notion of a causal relationship of within-session (performance)
and between-session (progress) extinction.
Analysis of the mechanisms underlying extinction learning
and the resulting conditions that facilitate or impair extinction
may help to unravel the relationship between extinction perfor-
mance and extinction progress and to refine exposure-based
therapies. Therefore, the present study tried to dissect within-
session and between-session extinction in mice with or without
intact CB1 signaling in extinction paradigmswith different expo-
suremodalities.Weprovide evidence that spaced extinction trials
are most efficient in eliciting between-session extinction. More-
over within-session extinction turned out to be neither sufficient
nor essential for between-session extinction. In addition, we
demonstrate that CB1 signaling controls within-session extinc-
tion but is largely dispensable for between-session extinction. By
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combining these results, we identified anatomical signatures of
extinction training.
Materials andMethods
Animals
We used a total of 118male C57BL/6NCrl (B6N purchased fromCharles
River Deutschland) and 28male CB1 receptor-deficient (CB1/) mice,
and 28male wild-type littermates (CB1/; sample sizes for the individ-
ual experiments are given in the figure legends). Mutant mice and litter-
mate controls were generated/genotyped as described before (Marsicano
et al., 2002) and originated from our institutional breeding stock, which
had been backcrossed to the B6N strain for six generations. At an age of
6–7 weeks, mice were separated and housed individually with food and
water ad libitumunder an inverse 12:12 h dark/light cycle (light off at 9:00
A.M.). Experiments were performed at an age of 9–12 weeks.
Behavioral procedures
All experimental procedures were approved by the Committee on
Animal Health and Care of the State of Bavaria (Regierung von Ober-
bayern) and performed in strict compliance with the European Union
recommendations for the care and use of laboratory animals (86/609/
CEE). Experiments were performed during the activity phase (i.e.,
dark phase) of the animals between 9:30 A.M. and 5:00 P.M. Animals
of a given experiment derived from the same batch of mice and were
tested simultaneously.
Fear conditioning. For conditioning, mice were placed in the condi-
tioning context (Kamprath and Wotjak, 2004). Three minutes later, a
tone (80 dB, 9 kHz sinewave, 10ms rising and falling time)was presented
to the animals for 20 s that coterminated with a 2 s scrambled electric
footshock of 0.7 mA. Mice were returned to their home cages (hc) 60 s
later.
Extinction training. Extinction procedures were adapted from Kam-
prath andWotjak (2004) for permanent tone procedure, and fromHerry
et al. (2006) for variable interval procedure. Briefly, mice were placed in
the test context, which differed from the conditioning context in mate-
rial, shape, surface texture, and odor of the cleaning solution. After an
initial 3 min of habituation, they were confronted either with a perma-
nent 200 s tone [9 kHz, 80 dB, sine-wave; permanent tone (pt)] or with
ten 20 s tones of the same characteristics presented with either constant
intertone intervals (ci) of 20 s or variable tone intervals (vi) ranging from
20 to 180 s (mean, 80 s).Mice returned to their hc 60 s after the end of the
exposure protocol (see also Fig. 2A).
Experiments
Experiment 1. B6N mice were conditioned at day 0 (d0) and randomly
assigned to one of three groups, which differed in extinction procedures
at day 1 and day 2. Group I was exposed to a single pt, group II to ten 20 s
tones with ci, and group III to ten 20 s tones with vi per day. At day 3, all
animals were exposed to a single 20 s tone (for details, see Fig. 2A).
Experiment 2. B6N animals were conditioned at day 0 and randomly
assigned to one of two groups, which differed in extinction procedures at
day 40 and day 41. Group I was exposed to a single pt, group II to ten 20 s
tones with vi. At day 42, all animals were exposed to a single 20 s tone.
Experiment 3. For the first part of the experiment, CB1/ and
CB1/ mice were conditioned at day 0 and were exposed to a single
200 s tone per day (pt) on days 1, 2, 3, 10, and d40. For the second part,
B6N mice were conditioned at d0 and randomly assigned to one of two
groups.One groupwas treatedwith vehicle (Veh), the otherwith theCB1
receptor antagonist SR141716 (SR; 3 mg/kg, s.c.) 1 h before exposure to
a single 200 s tone (pt) on days 1, 2, 3, 10, and 40.
Experiment 4. For the first part of the experiment, CB1/ and
CB1/ mice were conditioned at day 0 and exposed to ten 20 s tones
with vi on days 1, 2, 3, 10, and 40. For the second part, B6N mice were
conditioned at day 0 and randomly assigned to one of two groups. One
group was treated with Veh, the other with the CB1 receptor antagonist
SR (3 mg/kg, s.c.) 1 h before exposure to ten 20 s tones with vi on days 1,
2, 3, 10, and 40.
Experiment 5. B6N mice were conditioned at day 0 and randomly
assigned to one of six groups, which differed in extinction procedures
and drug treatment. Injection took place 1 h before exposure on day 1,
when group I received a single 200 s tone (pt) after Veh injection, group
II a single 200 s tone (pt) after SR injection (3 mg/kg, s.c.), group III ten
20 s tones with vi after Veh injection, and group IV ten 20 s tones with vi
after SR injection. Groups V and VI also received Veh and SR injections,
respectively, but were left in their hc. All mice were processed for c-Fos
immunohistochemistry 70 min after the end of extinction training (or
the respective time in the home cage).
Behavioral analysis
The behavior of the mice was videotaped and scored off-line by a trained
observerwhowas blind to the animals’ treatment/genotype. Freezingwas
defined as the absence of all movements, except for those related to
respiration.
c-Fos immunohistochemistry
Mice were deeply anesthetized with a mixture of ketamine/xylazine and
transcardially perfused. Brains were removed, postfixed in 4% formalde-
hyde diluted in PBS for 20 h and transferred to 1 M sucrose in PBS for
another 20 h. The brains were shock frozen in isobutanol and stored at
80°C until cryosectioning. Floating frontal sections (40 m) were in-
cubated with an antibody raised against a peptide mapping at the N
terminus of human c-Fos p62 (identical to the corresponding mouse
sequence; c-Fos sc-42; 1:20000; SantaCruz Biotechnology) for 4 d. c-Fos-
immunoreactive cells were visualized using a biotinylated goat anti-
rabbit secondary antibody (1:2000, Jackson Laboratory) and the ABC
method (Richter et al., 2005). The number of c-Fos-immunoreactive
cells was determined using a Zeiss microscope (Axiophot) and a com-
puter program (ImageJ; http://rsbweb.nih.gov/ij/). The following brain
areas were analyzed: dentate gyrus (DG) and CA3 regions of the dorsal
hippocampus, basolateral amygdala (BLA), lateral amygdala (LA), cen-
tral amygdala (CeA), cingulate cortex (Cg1), prelimbic cortex (PrL), and
infralimbic cortex (IL) (Franklin and Paxinos, 1997) (see Fig. 6D). The
total number of c-Fos-positive cells was counted within the regions of
interest (ROIs) in both hemispheres on one representative section per
mouse and ROI. Sections and ROIs were identified by combining dark-
field pictures, bright-field pictures, and schematic drawings from a
mouse brain atlas (Franklin and Paxinos, 1997) (for details, see Fig. 1).
Sectionswere chosen and analyses performed unaware of the experimen-
tal history. The specificity of the staining procedure was confirmed by
omission of the primary antibody (data not shown).
Drug treatment
SR141716 (Rimonabant) (Rinaldi-Carmona et al., 1994), kindly pro-
vided by the National Institute ofMental Health Chemical Synthesis and
Drug Supply Program, was dissolved in vehicle solution (2.5% DMSO
and 1 drop of Tween 80 per 3ml of saline) and injected subcutaneously at
3 mg/kg body weight 1 h before each extinction training. For all groups,
injections were given under light isoflurane anesthesia to avoid differ-
ences in coping with the stressful injection procedure betweenmice with
intact and abolished CB1 signaling.
Figure1. Localization of c-Fos-positive cells in the regions of interest. As shown exemplarily
for the basolateral and central amygdala complex, ROIs were selected according to the mouse
brain atlas (Franklin and Paxinos, 1997). Dark-field and bright-field pictures of the same slide
were taken and overlaidwith brain atlas figures to visualize the boundaries of the ROIs together
with the c-Fos-positive cells.
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Statistical analysis
Freezing behavior was analyzed in 20 s intervals and expressed as a per-
centage of the respective analysis interval. The following measures were
considered for describing within- and between-session extinction: (1)
changes in the total freezing response to the tone(s) over the course of the
extinction training days (traditionally used measure of between-session
extinction), (2) changes in freezing over the course of tone presenta-
tion(s) per day (in 20 s intervals; within-session extinction), and (3)
changes in the initial freezing response to the first 20 s of tone presenta-
tion per day (defined by the length of the CS during conditioning) over
the course of the extinction training days (newly suggested measure of
between-session extinction). Data were analyzed by one-way ANOVAs
for repeated measures (time), two-way ANOVAs (protocol/genotype/
treatment, time) for repeated measures (time interval) separately per
test day (analysis of the freezing data in 20 s intervals), or two-way ANO-
VAs (protocol/genotype/treatment, time) for repeated measures (time 
analysis of the development of the total freezing responses/the initial
freezing responses shown during the first 20 s of tone presentation over
the course of the repeated training/testing days). c-Fos data were ana-
lyzed by two-way ANOVA (protocol, treatment) separately for each
brain structure. Post hoc comparisons were performed by the Newman–
Keuls test, if appropriate. Statistical significance was accepted if p 
0.05. Statistical analyseswere performedusing specialized software (Graph-
Pad Prism 5.0, StatSoft Statistica 5.0, and SPSS version 16.0).
Results
Within-session extinction is not sufficient for initiating
between-session extinction of recent fear memories
To study the interrelation of within- and between-session extinc-
tion, we conditionedmale B6Nmicewith a single pairing of a 20 s
tone with a footshock. The next 2 days, mice were re-exposed to
the tone for a total of 200 s per day. Tones were presented either
as a single 200 s pt or as series of 10 20 s tones with ci or vi (Fig.
2A). All mice were exposed to a single 20 s tone at day 3. All three
groups showed the same decline in freezing on day 1 of extinction
training (time: F(9,243)  22.5, p  0.001), independently of the
protocol (protocol: F(2,27)  0.81, p  0.921; protocol  time:
F(18,243) 0.71, p 0.789) (Fig. 2C). Despite these similarities in
within-session extinction, groups differed significantly in
between-session extinction (protocol time: F(2,27) 6.37, p
0.005) (Fig. 2B) and in the development of initial freezing re-
sponses (protocol  time: F(4,54)  6.91, p  0.001) (Fig. 2D).
Post hoc analyses revealed that between-session decline in freez-
ing was most pronounced in mice with repeated daily tone pre-
sentations at variable intervals, significantly retarded following
tone presentations at constant intervals, and virtually absent in
the case of permanent tone presentations. These data indicate
that the predictability of tone presentations retards between-
session extinction and that within-session extinction per se is
not sufficient for initiating between-session extinction.
Within-session extinction is not essential for initiating
between-session extinction of remote fear memories
To test whether our conclusions also apply to extinction of re-
mote fearmemories, we conditionedmale B6Nmicewith a single
tone–shock pairing at day 0 and exposed them either to a single pt
of 200 s or to series of 10 20 s tone with vi at day 40 and day 41
after conditioning, followed by exposure to a single 20 s tone at
day 42. Both groups showed a similar nondecaying freezing re-
sponse at day 40 (protocol: F(1,14) 0.39, p 0.845; time: F(9,126)
1.25, p 0.269; protocol time: F(9,126) 1.01, p 0.428) (Fig.
3B). At days 41 and 42, however, mice of the vi group showed
significantly less freezing than mice of the pt group ( p 0.005).
This was reflected by reduced total freezing (protocol  time:
F(1,14)  13.96, p  0.002) (Fig. 3A) and significantly decreased
initial freezing responses in the vi group (protocol: F(1,14) 
22.15, p 0.001; protocol time: F(2,28) 4.69, p 0.017) (Fig.
3C). Mice of the pt group failed to develop between-session ex-
tinction despite prominent within-session extinction at day 41
(Fig. 3B,C). Thus, within-session extinction is also not sufficient
for initiating between-session extinction in cases of remote fear
memories. Moreover, the fact that the initial freezing response
decreased in the vi group from day 40 to day 41 in the absence
of within-session extinction at day 40 demonstrates that within-
session extinction is not necessary for initiating between-
session extinction.
CB1 receptor signaling mediates within-session but not
between-session extinction
To further validate our conclusions, we studied fear extinction in
mice with abolished CB1 receptor signaling, an animal model of
severe impairments in within-session extinction. In agreement
with previous observations (Kamprath et al., 2006, 2009), both
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Figure 2. Extinction training as a function of stimulus length, repetition, and predictability.
A, Experimental schedule depicting that B6N mice received a single tone–shock pairing at d0
and were subsequently exposed to one of three tone presentation protocols at d1 and d2,
followed by a final 20 s tone presentation at d3 (n 10 per group).B, Development of the total
freezing responses over the course of repeated extinction training. C, Development of the freez-
ing responses over the course of tone presentations per day (note that freezing to the 200 s tone
was analyzed in 20 s bins). D, Development of the freezing responses to the initial 20 s of tone
presentations per day. The duration of freezing was normalized to respective observation peri-
ods and presented as the mean SEM. Results of the two-way ANOVA for repeated measure-
ments with the main factors protocol (P) and time (T) are shown in the graphs (for the sake of
clarity, we do not report the results of post hoc analyses).
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genetic (genotype time: F(9,189) 1.92, p 0.05) (Fig. 4B) and
pharmacological prevention of CB1 receptor signaling (treat-
ment: F(1,19)  7.47, p  0.01) (Fig. 4E) rendered conditioned
mice unable to show within-session extinction over the course of
a permanent tone presentation. Between-session extinction was
considerably more pronounced in wild-type than in CB1-
deficient mice if the development of the total freezing responses
was considered (time: F(9,84) 10.05, p 0.001; genotype: F(1,21)
 6.16, p 0.021; two-way ANOVA) (Fig. 4A). Also in vehicle-
treated controls, the total freezing response was significantly
smaller than in B6N mice treated with the CB1 receptor antago-
nist SR141716 (treatment: F(1,19) 21.37, p 0.001) (Fig. 4D).
In contrast to development of the total freezing responses, we
failed to observe any significant decrease in the initial freezing
responses to the tone, regardless of the genotype (genotype:F(1,21)
 1.03, p  0.320; time: F(9,84)  1.68, p  0.160; genotype 
time: F(9,84) 1.30, p 0.273) (Fig. 4C) or treatment (treatment:
F(1,19)  7.36, p  0.013; time: F(4,76)  1.84, p  0.129; treat-
ment time: F(4,76) 0.99, p 0.413) (Fig. 4F) of the animals.
These data corroborate our previous findings that within-session
extinction is not sufficient for between-session extinction even
under circumstances of more intensified extinction training.
Genetic deletion or pharmacological blockade of CB1 also pre-
ventedwithin-session extinction in the case of extinction training by
repeated20s tonepresentationsatvariable intervals (day1:F(9,135)
1.43, p  0.179, in the case of CB1/ mice; day 1 and day 2:
F(9,81) 1.98, p 0.05, in the case of treatment with SR141716),
except for day 2 in CB1/mice, when within-session extinction
was attenuated but not abolished (F(9,135)  2.10, p  0.038,
one-way ANOVAs performed separately per group) (Fig. 5B,E).
In contrast, wild-type and vehicle-treated controls showedprom-
inent within-session extinction at day 1 and day 2 (F(9,144) 9.69,
p 0.0001, in the case of CB1/mice; F(9,99) 3.62, p 0.001,
in the case of vehicle treatment), before they reached floor levels
of freezing behavior (d3). Accordingly, freezing responses were
always significantly more pronounced in wild-type (genotype:
F(1,31)  5.93, p  0.020, d1, d2, d3, and d40) (Fig. 5B) and
vehicle-treated mice (treatment: F(1,20)  9.89, p  0.005, d1 to
d40) (Fig. 5E). Despite the impairments in within-session extinc-
tion, genetic deletion of CB1 failed to affect between-session ex-
tinction. This became evident if the development of the total
freezing responses (genotype: F(1,31)  12.13, p  0.001; time:
F(4,124) 111.5, p 0.001; genotype time: F(4,124) 0.89, p
0.470) (Fig. 5A) or the initial freezing responses (genotype: F(1,31) 
3.44, p 0.072; time: F(4,124) 74.98, p 0.001; genotype time:
F(4,124) 1.89, p 0.115) (Fig. 5C)were considered. Essentially, the
same was the case after pharmacological blockade of CB1 (Fig.
5D,F) (statistics not shown). All animals showed spontaneous re-
covery of the freezing response from day 10 to day 40, which was
more pronounced in antagonist-treatedmice, if development of the
total freezing response was considered (treatment time: F(4,72)
3.81, p  0.007) (Fig. 5D). Together, these data demonstrate that
CB1 receptors play an important role in within-session extinction
notonlyduringexposure topermanent tones, but alsowith repeated
tone presentations at variable intervals, without affecting between-
session extinction. This strengthens our previous conclusion that
within-session extinction is neither necessary nor sufficient for
between-session extinction.
Neuroanatomical basis of relearning
By combining pharmacological blockade of CB1 receptors with
the pt and vi protocols, we ought to dissociate anatomical sub-
strates of within-session and between-session extinction. In
agreement with our previous observations, a three-way ANOVA
(protocol, drug, time) for repeated measures (time) confirmed
that mice failed to show within-session extinction after treatment
with SR141716,whereas vehicle-treated controls showed a rapid de-
cline in freezing (drug: F(1,36)  98.88, p  0.001; drug  time:
F(9,324)  34.51, p  0.001), with no differences between the two
extinction protocols (protocol: F(1,36)  0.043, p  0.835; proto-
col drug: F(1,36) 0.044, p 0.834; protocol time: F(9,324)
1.33, p 0.216; protocol drug time: F(9,324) 1.19, p 0.300)
(Fig. 6, insets). Freezingbehavior before tonepresentationswasneg-
ligible and unaffected by pharmacological treatment (Fig. 6, insets)
(statistics not shown).
Consequences of permanent versus repeated tone presenta-
tions and pharmacological treatment on neuronal activity were
assessed by counting the number of c-Fos-immunoreactive neu-
rons (Fos-ir). We focused our attention on those brain areas that
are known to be involved in fear and relearning processes,
namely, the hippocampal formation, the amygdala complex, and
the prefrontal cortex (Singewald, 2007). Two-way ANOVAs with
the factors protocol (presentation of permanent tone vs repeated
tone presentations vs home-cage controls) and treatment
(SR141716 vs vehicle) revealed highly significant main effects of
protocol for most of the brain structures under study (F(2,27) 
3.84, p  0.05) (Fig. 6C). Post hoc analyses failed to detect any
significant differences in Fos-ir betweenmice exposed to the per-
manent tone and home-cage controls, except for the CA3 region
of the hippocampus and the lateral amygdala (Fig. 6A,B). Re-
peated exposure to 20 s tones, in contrast, led to a significant
increase in Fos-ir in the dentate gyrus, the basolateral and lateral
amygdala, the cingulate cortex, and the prelimbic cortex, com-
pared with mice exposed to a single 200 s tone and to home-cage
controls. As indicated by the lack of protocol treatment inter-
actions in most of the brain structures (F(2,27) 2.17, p 0.133,
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Figure 3. Extinction training after fear incubation. B6N mice received a single tone–shock
pairing at d0 andwere exposed to either a pt of 200 s duration (n 9) or ten 20 s tones with vi
(n 7) at d40 and d41. At d42, all mice were exposed to a single 20 s tone. A, Development of
the total freezing responses over the course of repeated extinction training. B, Development of
the freezing responses over the course of tone presentations per day. C, Development of the
freezing responses to the initial 20 s of tone presentations per day. Datawere normalized to the
respective observation interval and expressed asmeans SEM. Results of the two-wayANOVA
for repeated measurements with the main factors protocol (P) and time (T) are shown in the
graphs (for the sake of clarity, we do not report the results of post hoc analyses).
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except for IL) (Fig. 6C), these activity pat-
terns were largely independent of treat-
ment with the CB1 receptor antagonist.
However, pharmacological blockade of
CB1 led to a general increase in Fos-ir
within the CA3 region (weak effect; F(1,27)
5.98, p  0.021), lateral amygdala, central
amygdala, and prelimbic cortex (strong
effects; F(1,27)  21.7, p  0.001) (Fig.
6A,B), independently of the protocol
used (i.e., even in home-cage controls).
Only in the case of the infralimbic cortex
was there a significant interaction between
protocol and treatment (F(2,27)16.95,p
0.001). Whereas vehicle-treated mice with
repeated tone presentation showed in-
creased Fos-ir compared with the two
other groups, this difference was abol-
ished by treatment with the CB1 receptor
antagonist. Together, freezing to the tone
in vehicle-treated mice and precipitation
of exaggerated freezing by pharmacologi-
cal blockade of CB1 failed to reveal signif-
icant differences in Fos-ir between mice
exposed to the permanent tone and re-
spective home-cage controls. Conse-
quently, expression of freezing per se was
not reflected by Fos-ir in the brain
structures under study. Repeated tone
presentations at variable intervals led to
a significant increase in Fos-ir in a num-
ber of brain structures, compared with
mice exposed to a permanent tone. In
the dentate gyrus, basolateral amygdala,
and cingulate cortex, these differences
were largely independent of the phar-
macological blockade of CB1 and
within-session extinction of freezing be-
havior, suggesting those brain struc-
tures as primary places of between-
session extinction. Finally, some brain
structures, such as the prelimbic cortex and central amygdala,
showed a general increase in Fos-ir on pharmacological block-
ade of CB1 even in home-cage controls, thus indicating their
general involvement in processing of stressful encounters
(e.g., injection procedure).
Discussion
The present study investigated the interrelation betweenwithin-
session and between-session extinction in an auditory-cued fear-
conditioning paradigm. We showed that within-session
extinction was the same for permanent and spaced tone presen-
tations. It required intact CB1 signaling andwas neither sufficient
nor necessary for initiating between-session extinction. Between-
session extinction, in contrast, depended on the pattern and pre-
dictability of tone presentations. It was maintained in mice with
disrupted CB1 receptor signaling and developed independently
of within-session extinction. The dissociation of within- and
between-session extinction could also be seen at the neuroana-
tomical level in terms of c-Fos expression.
The striking similarities in within-session extinction in re-
sponse to permanent (pt) and spaced (ci and vi) tone presenta-
tions at day 1 indicate that the decline in freezing over the course
of a given extinction session likely relates to the total duration and
not to the pattern of tone presentation. It might result from the
same short-term habituation processes (Kamprath and Wotjak,
2004). Only spaced tone presentations led to between-session
extinction. Apparently, repeated experience of the tone–no-
shock association (vi and ci) is more efficient in establishing an
inhibitory memory trace than a single tone presentation per day
(pt). Consequently, the absence of the predicted punishment
rather than acute fear relief per se seems to cause the formation of
a CS–no-US association.
Repeated tone presentations at vi were more efficient in elic-
iting between-session extinction than tone presentations at ci.
This might be explained by the role of attention in extinction
learning. For instance, some authors propose that focusing atten-
tion on the fear stimulus favors fear reduction (Kamphuis and
Telch, 2000), which, however, is disputed by others (Oliver and
Page, 2003). In the present study, unexpected stimulus presenta-
tion may raise attention toward the tone, whereas tone presenta-
tions at regular intervals may favor stimulus expectancy and,
thus, reduce attention. In this context, it is of note that temporal
predictability could promote habituation of neuronal activity in
brain structures such as the lateral and basolateral amygdala
Figure 4. Role of CB1 in extinction training with permanent tones. All animals received a single tone–shock pairing at d0
and were subsequently exposed to the pt protocol (compare Fig. 2 A) from d1 to d40. A–F, CB1 receptor signaling was
abolished by either genetic means (A–C) or the CB1 receptor antagonist SR141716 (3 mg/kg, s.c.), which was administered
to B6N mice 1 h before tone presentations at d1 to d40 (D–F ). Analysis of the development of the total freezing responses
over the course of repeated extinction training (A, D), the development of the freezing responses over the course of tone
presentations per day (analyzed in 20 s bins) (B, E), and the development of the freezing responses to the initial 20 s of tone
presentations per day (C, F) of CB1-deficient mice (KO; n 12), wild-type littermates (WT; n 11), and B6N mice with
pharmacological blockade of CB1 (SR; n 11) or vehicle treatment (n 10). Data were normalized to the respective
observation interval and expressed as means SEM. Results of the two-way ANOVA for repeated measurements with the
main factors genotype (KO), treatment (SR), and time (T) are shown in the graphs (for the sake of clarity, we do not report
the results of post hoc analyses).
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(Herry et al., 2007), which had been implicated in extinction
learning (Falls et al., 1992; Herry et al., 2008).
Fear incubation for several weeks led to a sustained freezing
response to the tone. Other than for contextual fear memory
(Woods andBouton, 2008), little is known about the dependency
of fear extinction on the age of cued fear memories. The only
exceptions are studies investigating consequences of extinction
training initiated early after conditioning (e.g., Myers et al., 2006;
Kim and Richardson, 2009). Here, we demonstrate that mice
showed decaying freezing 1 d after but sustained freezing 40 d
after the tone–shock pairing, regardless of the tone presentation
protocol (pt vs vi). Contextual fear memory is known to un-
dergo major reorganization between recent and remote stages
(Frankland et al., 2004). For instance, remote contextual
memories are stored in distributed cortical networks (Woods
and Bouton, 2008). It remains to be shown whether auditory-
cured fear memory undergoes similar changes and whether
these changes are the cause for the less efficient within-session
extinction at late time points after conditioning.
Despite the complete absence of within-session extinction at
day 40, tone presentation at variable intervals readily elicited
between-session extinction, thus indicating that within-session
extinction is not only insufficient (as discussed before), but also
dispensable for initiation of between-session extinction. This
finding points to an uncoupling of fear
expression and cognitive appraisal of
changes in CS–US contingencies, which is
supported by the results obtained in mice
with genetic deletions or pharmacological
blockade of CB1 receptors. Those inter-
ventions abolished or severely attenuated
within-session extinction but failed to af-
fect between-session extinction triggered
by repeated tone presentations at variable
intervals. The phenotype seen in within-
session extinction precludes that the lack
of involvement of CB1 in between-session
extinction relates to inefficient activation
of the endocannabinoid system (Kam-
prath et al., 2009). It rather implies that
CB1 signaling is dispensable for relearn-
ing of theCS–US contingency, similarly to
the situation in appetitive conditioning
tasks (Ho¨lter et al., 2005). This conclusion
seemingly contradicts numerous studies
reporting a significant role of the endo-
cannabinoid system in between-session
extinction (Viveros et al., 2007; Moreira
and Lutz, 2008). To resolve this issue,
we propose that extinction of elemental
fear memories follows different rules than
extinction of contextual/hippocampus-
dependent memories. Furthermore, the
impairments of CB1-deficient mice in
between-session extinction of auditory-
cued fear memories reported before
(Marsicano et al., 2002) might be ex-
plained by an involvement of the endo-
cannabinoid system in habituation to
homotypic stressors (Patel and Hillard,
2008). Repeated confrontation with the
same aversive encounter is accompanied
by increased endocannabinoid signaling,
which facilitates acute habituation to the stressor (Patel et al.,
2005b). A similar scenario may apply to fear extinction (Kam-
prath et al., 2006), where group differences between CB1-
deficient mice and wild-type controls became stronger on
repeated tone presentation (Fig. 4B). This accelerated within-
session extinction seemingly results in between-session extinc-
tion, if development of the total freezing responses is considered
(Fig. 4A), but does not affect the initial freezing responses per day
(Fig. 4C). Our failure to observe a similar acceleration of within-
session extinction in vehicle-treated controls (Fig. 4D) might
be explained by summative effects of exposure to the tone and
stressful injection procedure, which may result in an almost
maximal activation of the endocannabinoid system right from
the beginning of extinction training.
If extinction training indeed leads to relearning of the tone–
shock contingency and the formation of a new inhibitory tone–
no-shock association that suppresses the expression of the
original memory trace (Myers and Davis, 2002, 2007; Ehrlich et
al., 2009), we should expect decreased fear responses right from
the beginning of the tone presentation. Therefore, we propose
that the development of the initial fear responses to the tone over
the course of repeated extinction training represents the most
direct measure of between-session extinction. This measure is
superior to analysis of total fear responses, since it is not con-
Figure 5. Role of CB1 in extinction trainingwith repeated tone presentations at variable intervals. All animals received a single
tone–shock pairing at d0 and were subsequently exposed to ten 20 s tones at vi (compare Fig. 2A) from d1 to d40. A–F, CB1
receptor signalingwas abolished either by geneticmeans (A–C) or by the CB1 receptor antagonist SR141716 (3mg/kg, s.c.),which
was administered to B6Nmice 1 h before the first tone presentation at d1 to d40 (D–F ). Analysis of the development of the total
freezing responsesover the courseof repeatedextinction training (A,D), thedevelopmentof the freezing responsesover the course
of tone presentations per day (B, E), and the development of the freezing responses to the first 20 s tone per day (C, F) of
CB1-deficient mice (KO; n 16), wild-type littermates (WT; n 17), and B6N mice with pharmacological blockade of CB1 (SR,
n 10) or vehicle treatment (n 12). Datawere normalized to the respective observation interval and expressed asmeans SEM.
Resultsof thetwo-wayANOVAfor repeatedmeasurementswiththemainfactorsgenotype(KO), treatment(SR),andtime(T)areshownin
the graphs (for the sake of clarity,wedonot report the results ofpost hoc analyses).
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founded by differences in within-session extinction (as discussed
before). Accordingly, the reoccurrence of the freezing response
with the passage of time (i.e., spontaneous recovery) should be
assessed bymeans of the initial fear responses rather than the total
fear responses. In any case, comparisons of freezing responses
shown at the end of an extinction session and the beginning of the
next have to be avoided because of the apparent independence of
within-session and between-session extinction revealed by the
present study.
We could dissociate within-session and between-session ex-
tinction not only at the behavioral andmolecular levels (in terms
of CB1 signaling), but also at the anatomical level. Exposure to
tones at variable intervals caused increased Fos-ir in the lateral
and basolateral amygdala, compared to mice with exposure to
permanent tones and to home-cage controls. A similar pattern of
Fos-ir was observed in the dentate gyrus, the cingulate cortex, and
the prelimbic cortex. However, only in the basolateral amygdala,
dentate gyrus, and cingulate cortex, Fos-ir was largely indepen-
dent of pharmacological blockade of CB1 receptors and/or dif-
ferences in expression of conditioned fear. Given the fact that
between-session extinction was unaffected by impairments in
CB1 signaling (Fig. 5C,F), these three brain structuresmight rep-
resent hot spots for relearning processes, which involve plastic
changes in neuronal activity. This conclusion is supported by
pharmacological studies reporting, for instance, that local inhi-
bition of NMDA receptors (Falls et al., 1992) or mitogen-
activated protein kinase activity (Herry et al., 2006) within the
basolateral amygdala impairs between-session extinction. Re-
cently,Hefner et al. (2008) performed a thorough investigation of
the neuronal matrix underlying extinction recall. They studied
Fos-ir in extinction-prone and extinction-resistantmouse strains
and reported significant strain differences primarily within the
basolateral amygdala and the infralimbic cortex. Consequently,
the formation of a new tone–no-shock association and recall of
this inhibitorymemory trace seems to involve, at least in part, the
same brain structures.
Pharmacological blockade of CB1 led to a large increase in
Fos-ir primarily within the central amygdala and prelimbic cor-
tex, regardless of the exposure protocol, i.e., even in home-cage
controls. These data provide compelling evidence that not only
freezing responses elicited by electrical stimulation or pharmaco-
logical manipulation of distinct brain structures (Vianna et al.,
2003; Borelli et al., 2006), but also expression of conditioned fear
fails to induce c-Fos expression in a variety of brain structures
known to be implicated in fear and anxiety (Singewald, 2007).
Other markers of neuronal activity, such as phosphorylation of
kinases, may better reflect differences in freezing behavior (in
particular if analyzed in the absence of injection stress inCB1-KO
and CB1-WT mice) (Cannich et al., 2004). Previous studies re-
ported an increase in Fos-ir in the central amygdala of naivemice
following pharmacological blockade of CB1 (Patel et al., 2005a).
In addition, CB1 plays a complex role in the regulation of fear and
anxiety within the medial prefrontal cortex (Lin et al., 2009), and
neuronal activity within the prelimbic cortex seems to directly
Figure6. Neuroanatomical signature of extinction training. B6Nmice received a single tone–shock pairing at d0 andwere exposed to either a pt of 200 s duration (compare Fig. 2A) or to ten 20 s
tones at vi (compare Fig. 2A), or stayed in their hc24h later (d1).A,B, Half of theanimals of eachgroupwere treatedwith vehicle (A), and theotherhalfwere treatedwith theCB1 receptor antagonist
SR141716 (3mg/kg) (B) 1 h before tone presentation (in the case of pt and vi). All animals were killed 70min after the end of the exposure (or after the same time in the home cage), and the brains
were processed for c-Fos immunohistochemistry (A, B). Insets show the development of the freezing responses before and during tone presentations, whereby freezing data of the animals of the
same treatment groups as used for immunohistochemistry in the respective figure panel are shown in black and those of the other treatment groups in gray. C, Results of the two-way ANOVAswith
the main factors protocol (P) and treatment (SR), performed separately per brain structure (p 0.05; p 0.05; p 0.01; p 0.001; #significant SR–protocol interaction).
D, The total numberof c-Fos-positiveneuronswas countedbilaterally in theROIs inone sectionpermouse. ROIsweredefinedaccording to themousebrainatlas (Franklin andPaxinos, 1997; compare
Fig. 1). Values are expressed as the mean SEM (n 5 per group).
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relate to acute fear expression (Vidal-Gonzalez et al., 2006;
Burgos-Robles et al., 2009). Therefore, the most parsimonious
interpretation of our data is that c-Fos expression at the level of
the CeA and PrL reflects impaired endocannabinoid signaling,
likely because of exaggerated stress responses and discomfort re-
sulting from the injection procedure (Steiner andWotjak, 2008).
Freezing performance per se is not mirrored by c-Fos. At the
level of the BLA, DG, and Cg1, finally, increased c-Fos expres-
sion reflects relearning of tone–shock contingencies (i.e.,
between-session extinction), independently of the acute freez-
ing response (i.e., within-session extinction) and/or disturbed
CB1 receptor functioning.
The infralimbic cortex was the only brain structure where we
observed a significant interaction between tone presentation and
antagonist treatment. Induction of between-session extinction
by repeated exposure to tones at variable intervals caused a sig-
nificant increase in Fos-ir within that brain structure, compared
with home-cage controls and exposure to a permanent tone.
Pharmacological blockade of CB1 abolished these effects. This is
a striking observation, since the infralimbic cortex undergoes
plastic changes during relearning/extinction training (Santini et
al., 2008), which are thought to underlie its subsequent involve-
ment in suppression of conditioned fear during extinction recall
(Milad and Quirk, 2002). However, in light of the largely intact
between-session extinction observed in mice with pharmacolog-
ical blockade of CB1 (Fig. 5F), attenuation of Fos expression
following treatment with SR141716might be of minor biological
significance for the behavioral phenotype in the present study. It
remains to be shown towhat extent the differences in Fos-ir in the
infralimbic cortex contribute to the reduced retention of fear
extinction observed in these animals if alterations in spontaneous
recovery of freezing from day 10 to day 40 are considered (Fig.
5D,F).
Together, our data reveal an uncoupling between the expres-
sion of conditioned fear and the relearning of tone–shock con-
tingencies at molecular, anatomical, and behavioral levels. This
asks for reconsideration of current strategies in exposure-based
therapies in human subjects. As proposed by Craske et al. (2008),
within-session fear reduction does not predict therapy success.
The apparent dissociation of emotional and cognitive processing
disproves exposure paradigms in which the length of an exposure
session is defined by the time point of maximal acute fear relief.
Protocols should rather favor fast and effective buildup of inhib-
itorymemory traces regardless of acute fear levels. Pharmacolog-
ical prolongation of endocannabinoid signaling (Di Marzo,
2008) may not directly affect the inhibitory learning process, but
may reduce the emotional load during an exposure session and,
thus, increase compliance rates.
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Abstract
When retrieved, well consolidated memories are returned to a fragile state and need to be 
consolidated again in order to be maintained. This process is refered to as reconsolidation. 
Recently it was shown that during this period fear memories can be edited out. However 
most drugs interfering with reconsolidation have severe side effects and cannot be readily 
used in humans. In our study we inhibited PKC activity during extinction training and 
showed that it caused a prolonged increase of between-session extinction and abolished 
spontaneous recovery. By c-Fos immunohistochemistry we could show a specific, drug 
dependent, down-regulation of the cingulate cortex, irrespective of exposure protocols. 
The results suggest, that PKC activity in the CG1 could mediate mechanisms, which lead 
to relapse after fear extinction.
Introduction
A newly formed memory is stabilized for long term storage through a process called 
memory consolidation. During consolidation transcription and de novo protein synthesis 
occur and inhibition of either of these processes specifically blocks long term memory. It 
was long considered that a memory undergoes consolidation only once and that 
subsequently it would be permanent and unmodifiable. However this theory has been 
challenged by the finding that reactivation of a consolidatied memory can return it to a 
labile state. Thus, memory reactivation induces a second consolidation process which has 
been named reconsolidation (Alberini, 2005; Alberini et al., 2006;  Monfils et al., 2009; 
Nader and Einarrson, 2010).
We all have memories that we would rather forget. Most of us learn to cope with these 
memories but some of us cannot. Research on changing fears has highlited several 
techniques with most relying on the inhibition of the learned fear response. A problem with 
theses techniques is that the fear is likely to return, even after a significant fear reduction 
at the end of an exposure paradigm. Recent research showed that the return of fear can 
be prevented by update mechanisms which induce reconsolidation (Schiller et al., 2010). 
These findings demonstrate the role of reconsolidation as a window of opportunity to 
rewrite emotional memories.
A likely canidate for beeing involved in reconsolidation processes is the PKC familiy of the 
Ser/Thr kinases.  Protein Kinase C (PKC) is involved in synaptic remodelling, induction of 
protein synthesis and many other processes important in learning and memory (Olds et al., 
1989; Alkon, 1998; Bonini 2005 and 2007). Tronson et al. reported that if mice were 
injected with a PKC inhibitor after context fear conditioning but before extinction, fear 
decrease was facilitated. The effect was more pronounced in extinction prone mice 
(Tronson et al., 2007). Also PKC is reported to modulate NMDA receptor translocation. 
Animal studies have identified N-methyl-D-aspartate (NMDA) receptors as crucial in fear 
memory acquisition and consolidation, as well as in its extinction and reconsolidation. 
Based on this, the NMDA receptor partial agonist D-cycloserine, which facilitates fear 
extinction in rodents, has been shown to increase the effect of exposure therapy in 
psychiatric patients for conditions such as phobias, social anxiety and obsessive-
compulsive disorder (Amaral and Roesler, 2008).
Understanding the influences of PKC activity during fear extinction consolidation and 
reconsolidation could led a step further in treatment of anxiety disorders.
In a recent study (Plendl and Wotjak, 2010) we compared two extinction paradigms. Both 
produced within session extinction, but only one elicited between extinction consolidation 
and led to a decrease of initial fear level in further extinction sessions. Reconsolidation, 
which is definded as a reactivation of the original memory trace, should occur in both 
paradigms. So we should be able to differentiate between two mechanisms. First, the 
extinction consolidation process, which occurs only after an appropriate extinction training, 
and secondly, the reconsolidation process, which occures independently of the extinction 
training effectivity. For inhibition of PKC activity  we used GF109203X, which is reported to 
be highly specific (8-20 nM IC50). By using the above mentioned two different extinction 
protocols we should be able to dissociate the influence of PKC activity on consolidation 
and reconsolidation .
Materials and methods
Animals
We used male C57BL/6NCrl (B6N, purchased from Charles River Deutschland, Bad 
Sulzfeld, Germany). At an age of 6-7 weeks, mice were separated and housed individually 
with food and water ad libitum under an inverse 12:12 h dark-light cycle (light off at 09:00 
a.m.). Experiments were performed at an age of 9-12 week. 
Behavioural procedures
All experimental procedures were approved by the Committee on Animal Health and Care 
of the State of Bavaria (Regierung von Oberbayern) and performed in strict compliance 
with the European Union recommendations for the care and use of laboratory animals 
(86/609/CEE). Experiments were performed during the activity phase (i.e. dark phase) of 
the animals between 9:30 a.m. and 5:00 p.m. Animals of a given experiment derived from 
the same batch of mice and were tested simultaneously. 
Fear Conditioning: For conditioning, mice were placed in the conditioning context. Three 
minutes later, a 20s tone (80 dB, 9 kHz sine wave, 10 ms rising and falling time) was 
presented to the animals that co-terminated with a 2s scrambled electric foot shock of 0.7 
mA. Mice were returned to their home cages 60s later.
Extinction training: Extinction procedures were adapted from Plendl and Wotjak (2010). 
Briefly, mice were placed in the test context, which differed from the conditioning context in 
material, shape, surface texture and odor of the cleaning solution. After initial 3 minutes of 
habituation, they were confronted either with a permanent 200s tone (9kHz, 80dB, sine-
wave; pt, see Figure 1) or ten 20s tones, of the same characteristics, with varibale inter-
tone intervals of 20 to 180s (vi; see Figure 2).
Experiments
For a detailed description of behavioural experiment procedures please refer to figure 
legends.
Behavioral analysis 
The behavior of the mice was videotaped and scored off-line by a trained observer who 
was blind to the animals’ treatment. Freezing was defined as the absence of all 
movements, except for those related to respiration.
c-Fos immunohistochemistry
For detailed description of method see Plendl and Wotjak (2010) and figure legend (Figure 
3). Briefly, floating frontal cryosections (40µm) were incubated with c-Fos antibody 
(1:20000; Santa Cruz Biotechnology Inc., Santa Cruz, CF, USA) for 4 days. C-Fos 
immunoreactive cells were visualised using a biotinylated goat-anti rabbit secondary 
antibody (1:2000, Jackson Lab) and the ABC-method (Richter et al., 2005). 
Drug treatment
The PKC inhibitor GF109203X-hydrochloride (Sigma, Aldrich) was freshly aliquotet before 
each experiment in DMSO. Aliquots were freshly diluted before each experimental day in 
Ringer´s solution to reach the final concentration of 10 pmol/μl. A volume of 2µl of stock 
solution or control (2µl DMSO in Ringer´s solution) was injected 1h before experiments. 
The concentration for  i.c.v.  injection was based on previous reports  (Stemmelin  et  al.,  
1999; Blank et al., 2003).
Surgery
During surgery mice were deeply anaesthetised by inhalation of isoflurane. 1 hour before 
the procedure they recived aN injection of Ketamin. Body temperature was kept at a 
constant 36oC by a heating pad. The skull of the animal was exposed and a guide canula 
was implanted (1.0mm lateral to bregma, anterior 0.3mm, ventral 1.2mm). Additonally a 
screw was inserted into the skull. The guide cannula was fixed to the skull and the screw 
by dental cement. The wound was desinfected and closed with sutures. Mice were allowed 
to recover for 10-14 days before experiment and recieved analgetic treatment (Metacam) 
for 7 days after surgery via drinking water.
Statistical analysis 
Freezing behavior was analyzed in 20s intervals or for the entire tone presentation(s) per 
day and expressed as a percentage of the respective analysis interval. c-Fos data were 
analyzed by 2-way ANOVA (Protocol, Drug) separately for each brain structure and 3-way 
MANOVA (Protocol, Drug, Tone). Statistical significance was accepted if p < 0.05. 
Statistical analyses were performed by specialized software [GraphPad Prism 5.0 
(GraphPad, San Diego, CA), Statistica 5.0 (StatSoft, Tulsa, OK), and SPSS version 16.0 
(SPSS, Chicago, IL)].
Results
Inhibition of PKC-activity specifically promotes fear exinction in a time dependent  
manner and prevents spontaneous recovery and renewal
Even though vehicle-treated mice showed prominent within-session exinction upon 
exposure to a permanent tone at d1 and d2 after conditioning as well as on subsequent 
days in absence of treatment (d3, d40; F9,45<2.3; p<0.025; Figure 1A), between-session 
extinction (i.e. a decrease in the freezing response to the initial 20s of tone presentations 
per day over the course of repeated training) was virtually absend (F4,24=0.75; p=0,56). 
Treatment with GF109203X-hydrochloride (GF) before presentation of the permanent tone 
at d1 and d2 not only accelerated within-session extinction (d1: Drug x Time: F9,117=2.72; 
p=0.006), but also established between-session extinction (F4,28=9.96, p<0.005; Drug x 
Day: F4,28=9.96; p<0.005). Interestingly, there was no spontaneous recovery of the freezing 
response from d10 to d40 (F1,11=0.40, p=0.53).
We repeated this experiment with different groups of mice, but exposed the animals to the 
permanent tone in the original conditiong context at day 11 after conditiong (Figure 1B). 
Again, treatment with GF triggered between-session extinction (Drug x Day: F6,54=8.18, 
p<0.005), which became most prominent at day 10 (Drug x Time: F9,126=34.7, p<0.005). 
However, we failed to abserve renewal of the fear response at the next day upon testing in 
the conditioning context (Day: F1,7=0.162, p=0.7; Day x Time: F9,63=0.716, p=0.693; Figure 
1B). Contextual fear (as assessed by the freezing levels before tone presentation at d11) 
was indistinguishable between the two groups (GF: 28.4±8.5 vs. Veh: 38.02±7.4; 
F1,14=0.73, p=0,41). Compared to the last 20s of baseline freezing, vehicle controls 
showed a significant increase in freezing druing the first 20s of presentation (F1,8=23.51, 
p<0.005), whereas GF treated mice failed to do so (F1,6=0.75, p=0.48; Drug x Tone: 
F1,14=7.4, p=0.02; data not shown), indicating that GF treated mice failed to show renewal 
of the fear response. 
Drug treatment without re-activation of the fear memory at d1 and d2 had no 
consequences on expression of conditioned fear at d3 after conditioning, except for a 
slightly higher initial freezing response (Drug x Time: F9,243=1.86, p=0.057; Figure 1C). The 
same thing happenend, if mice were treated before exposure to a single 20s instead of the 
200s at d1 and d2 (d3; F1,9=0.86, p=0.37; Figure 1D). Acquisition of conditioned fear was 
unaffected by GF treatment (d1; Drug x Time: F9,171=0.94, p=0.84; Figure 1 E). Finally, GF 
failed to promote irrelevance learning (d1; Drug x Time: F9,180=1.6,  p=0.12; Figure 1F).
Inhibition of PKC activity before extinction training causes persistent attenuation of  
fear memories.
In accordacne with our previous observations (Plendl and Wotjak, 2010), extinction 
training of vehicle controls with ten 20s tone presentations per day at variable intervals 
was highly efficient in triggering between-session extinction (d1-d10; F3,24=55.66, p<0.005). 
GF treatment before extinction training at d1 and d2 failed to affect wihtin- and between-
session extinctoin (statistics not shown; Figure 2). However, whereas vehicle controls 
showed prominent spontaneous recovery of the freezing response to the initial 20s of tone 
presentation from d10 to d40 (F1,12=37.4, p<0.005), GF treated mice failed to do so 
(F1,12=0.008, p=0.92; Drug x Day: F1,16=66.26, p<0.005).
Activity in CG1 is decreased by PKC inhibition, independent of exposure protocol.
We employed c-Fos immunohistochemistry to identify the brain regions involved in the GF 
effects on extinction of conditioned fear (Figure 3). Conditioned mice were treated with GF 
or vehicle (Factor Drug) 1 h prior to exposure to a permanent 200s tone (series 1) or to ten 
20s tones at variable intervals (series 2; Factor Protocol). Exposure controls were treated 
in a similar manner, but exposed to the extinction context without tone presentations 
(Factor Tone). Since experiments were performed in two independent series (permanent 
vs. variable tone presentation), each series included its own exposure controls. All mice 
were killed 70 minutes after the end of the exposure and the brains processed for 
immunohistochemistry. To enable comparability of the results of the two series, we always 
expressed the number of c-Fos positive cells of a given brain structure as a perentage of 
the mean expression levels of the respective vehicle-treated exposure controls.
There was no difference in the freezing to the tone between the groups, irrespective of 
protocol or treatment during tone exposure (Protocol x Time: F9,207=1.83, p=0.064; Drug x 
Time: F9,207=0.423, p=0.92; Protocol x Drug x Time: F9,207=0.91, p=0.5; data not shown). A 
MANOVA (Protocol, Drug, Tone) over all Regions of Interest (ROI) revealed significant 
Protocol x Tone interactions in the LA, BLA, CEc, CEm, ITC, CG1 and PrL (F1,52>7.993, 
p<0.007; Figure 3A), indicating that exposure to the tones at variable intervals led to 
increased and exposure to the permanent tone to decreased or unchanged number of c-
Fos positive cells (see Figure 3 A for results and details of statistical analysis). Moreover 
significant Drug effects and Drug x Tone interactions were apparent exclusively in the CG1 
(Drug: F1,45=9.370, p=0.004; Drug x Tone: F1,45=5.756, p=0.021; Figure 3A+B).
Discussion
Repeated exposure to the permanent tones failed to induce between-session extinction. 
This is in accordance with our previous findings (Plendl and Wotjak, 2010). Treatment with 
GF turned a non-decaying fear response into a decaying fear response, which did not 
show spontaneous recovery or renewal. This process required activation of memory, since 
injections in the absence of reexposures of the tone did not lead to decreased fear.
These findings are reminiscent of disturbed reconsolidation rather than improved 
extinction processes (Nader and Hardt, 2009). Importantly the fact that the decrease of 
fear outlastet a period of 30 days after the last extinction training speaks against transient 
impariments in memory retrieval (Abel and Lattal, 2001). Noteworthy GF effects became 
evident in particular in the training sessions without further treatment (d3 and following). 
We cannot entirely rule out that GF was still active for days after treatment, however it 
would not be expected to last until day 40.
GF treatment failed to affect within- and between-session extinction following training with 
ten 20s tones at variable intervals. However, spontaneous recovery shown by vehicle-
treated controls was completely absent. This behavioural pattern is very similar to the 
recently described exposure protocol, where pre-exposure to the tone before extinction 
training caused a permanent loss of fear memory (Monfils, 2009). Again, the most 
parsimonious explanation of the data would be to assume impaired reconsolidation. This 
may also apply to the conversion of non-decaying  to decaying contextual fear, which has 
been described as evidence of improved extinction learning following PKC inhibition 
(Tronson et al., 2008).
GF seems to specifically interfere with reconsolidation, since it failed to affect memory 
acquisition, irrelevance learning and consolidation of extinction memory (Figure 1C-F). 
Such a specifitiy seems to be exceptional. Most of the known compounds to interfere with 
reconsolidation also impair memory acquisition or extinction learning (Diergaarde et al., 
2008). Some authors aurgue that consolidation and reconsoldation involve the same 
molecular processes (Nader and Einarrson, 2010). Our data do not support this notion but 
speak for reconsolidation specific molecular signature. Although, it is of note, that this 
finding might be task-specific (Bonini et al., 2007).
Analysis of the anatomical correlates of between-session extinction largely confirmed our 
previous observations (Plendl and Wotjak, 2010). Exposure to 20s tones at variable 
intervals coincided with increased c-Fos activity in the amygdala and the prefrontal cortex 
compared to exposure controls and mice exposed to the permanent tone. To our surprise, 
GF specifically affected c-Fos activity within the CG1, independent of the extinction 
training protocol. In each case there was a significant decrease in Fos-immunoreactivity 
(Figure 3B). The effects in other brain areas were less consistent. These findings suggest 
the CG1 as a crucial element in reconsolidation of fear memories. This does not imply that 
CG1 was the direct place of GF action, since changes in afferent brain structures may 
result in activity changes in the cingulate cortex. Nevertheless even a direct action within 
the CG1 is concieveable. The prefrontal cortex has a well established role in the inhibition 
of inappropriate responding (Rhodes and Killcross, 2007). It was shown that prefrontal 
long term potentiation (LTP), but not long term depression (LTD), is associated with the 
maintenance of extinction of conditioned fear (Herry and Garcia, 2002). This brings 
forward the idea that increased LTD could benefit spontaneous recovery. In the mPFC 
activation of muscarinic acetylcholine, which is known to be critical for cognitive 
performace, can induce long term depression of excitatory synaptic transmission. For LTD 
induction, the IP3 second messenger pathway, including PKC activation, is required 
(Huang and Hsu, 2009). Thus, inhibition of PKC activity could block the expression of LTD 
based mechanisms and thereby favour LTP processes which strengthen the maintenance 
of extinction memory and by this spontaneous recovery is abolished. 
Most drugs acting on reconsolidation are not specific and also impair acquisition, or 
extinction learning and may not be readily used in humans (Diergaarde et al., 2008). 
However, drugs acting on PKC are already in clinical use, though, not for treatment of 
anxiety disorders (Lithium Chloride,Valproic Acid) (Zarate and Manji, 2009). Our study 
suggests a new area of application for these drugs.
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Figure legends
Figure 1: Inhibition of PKC activity promotes fear reduction in a paradigm lacking 
exinction between-session extinction.
 All graphs show the development of the freezing responses over the course of the 
respective exposure days. Mice were treated with either GF109203X-hydrochloride or 
vehicle 1 hour before testing as indicated in the schemes (filled arrowheads) and were 
exposed to a 200s permanent tone. (A) Mice were injected on d1 and d2 and exposed to 
the tone on day 1 to d40.  (B) Test for renewal on d11. Mice were exposed to the tone on 
d1 to d10 in the extinction context and were treated before tone exposure on d1 and d2. 
On day 11 the context was changed to the conditioning context.  (C)  On d1 and d2 the 
animals were injected exposed to the context only, followed by tone presentation on d3. 
(D) Mice were injected on d1 and d2 exposed to only a single 20s tone each day. (E) Mice 
were injected on d0 before conditioning and tested on d1 in a drugfree state. (F) Mice were 
injected on d-2 and d-1 and presented to the 200s permanent tone in the conditioning 
context. On day1, after conditioning on d0, they were exposed to the tone in the extinction 
context. The duration of freezing was normalized to respective observation periods and 
presented as mean  SEM. Results of the 2-way ANOVA for repeated measurements with 
the main factors Drug (D) and Time (T) are shown in the graphs.
Figure 2: Inhibition of PKC does not interfere with between-session extinction but 
prevents spontaneous recovery. 
Development of the total freezing responses over the course of repeated extinction 
training. Animals treated with GF or vehicle, as described in Figure 1,  were exposed to ten 
single 20s tones with variable inter-tone-intervals on  d1 to d40.  The duration of freezing 
was normalized to respective observation periods and presented as mean  SEM. Results 
of the 2-way ANOVA for repeated measurements with the main factors Drug (D) and Time 
(T) are shown in the graphs.
Figure 3: Brain regions modulated by PKC inhibition.
B6N mice received a single tone-shock pairing at d0 and were exposed either to a 
permanent tone of 200s (pt) or ten 20s at variable interval (vi) (Protocol). Controls were 
exposed to the context only, without tone presentation (Tone: - (light exposure only), + 
(light + tone)). One hour prior exposure mice were injected either with Vehicle (veh, -) or 
GF109203X-hydrochloride (GF, +) (Drug). All animals were killed 70 minutes after the end 
of the exposur and the brains were processed for c-Fos immunohistochemistry.
The total number of c-Fos positive neurons was counted bilaterally in the Regions of 
Interest (ROI) from one section per mouse. ROIs were definded according to the mouse 
brain atlas (Franklin and Paxinos, 1997). LA, lateral amygdala; BLA, basolateral 
amygdala; CEl, latero-capsular subdivision of the central amygdala; CEm, medial 
subdivision of the central amygdala; ITC, intercalated cell cluster; CG1, cingulate cortex; 
PrL, prelimbic cortex; IL, infralimbic cortex; DG, dentate gyrus; CA3, CA3 region of the 
dorsal hippocampus
(A) Percentage of c-Fos immunoreactivity (IR) normalized to the mean of the vehicle/no-
tone group (veh-) ± SEM per ROI. 
(B) c-Fos immunoreactivity in the CG1 area of the medial prefrontal cortex (mPFC). 
Graphical presentation of the grey highlighted numerical values of Figure 3 A.
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MANOVA1)Veh- GF- Veh+ GF+ Veh- GF- Veh+ GF+
LA 100 ± 17 97 ± 21 69 ± 11 36 ± 8 100 ± 30 114 ± 22 230 ± 21 283 ± 36 PxT
BLA 100 ± 13 107 ± 20 63 ± 10 45 ± 10 100 ± 19 137 ± 20 200 ± 17 218 ± 23 PxT
CEl 100 ± 24 84 ± 32 56 ± 13 36 ± 16 100 ± 20 134 ± 44 291 ± 66  232 ± 123 PxT
CEm 100 ± 19 99 ± 26 47 ± 14  33 ± 10 100 ± 12 127 ± 33 188 ± 29  179 ± 44 PxT
ITC 100 ± 22 180 ± 71 104 ± 36 39 ± 10 100 ± 41 216 ± 42  277 ± 47  323 ± 108 PxT
CG1 100 ± 10 92 ± 12 108 ± 8 60 ± 16 100 ± 21 93 ± 14 336 ± 26  259 ± 14
PrL 100 ± 10 99 ± 4 99 ± 6 70 ± 15 100 ± 17 99 ± 11 169 ± 15  142 ± 16 PxT
IL 100 ± 16 94 ± 16 92 ± 17 46 ± 12 100 ± 26 77 ± 19 186 ± 31 190 ± 31 PxT
DG 100 ± 28 66 ± 16 80 ± 14 64 ± 14 100 ± 11 116 ± 9 101 ± 12 80 ± 12
CA3 100 ± 31 73 ± 16 88 ± 12 74 ± 20 100 ± 11 94 ± 13 118 ± 10 127±16
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Protocol (P; pt vs. vi), Drug (D; veh vs NP) and Tone presentations (T; - vs +) followed by between subjects and comparisons.
t: p<0.05 vs veh- of the same protocol (effect of the tone presentations)
d: p<0.05 vs veh- of the same protocol (effect of drug treatment)
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